signific
caus
death
australia
access
palli
care
limit
addit
previou
studi
indic
patient
chronic
lung
diseas
like
first
encount
palli
care
critic
care
set
aim
cabrini
hospit
develop
share
model
earli
referr
access
palli
care
patient
advanc
copd
integr
across
respiratori
continu
care
program
palli
homecar
team
enabl
patient
live
activ
possibl
focu
qualiti
life
reduc
time
hospit
optim
util
continu
care
servic
support
prefer
place
care
optim
function
comfort
physic
psychosoci
emot
spiritu
minim
physic
psychosoci
symptom
provid
adequ
knowledg
open
commun
patient
carer
help
time
inform
decisionmak
support
carer
throughout
person
ill
support
patient
carer
death
inevit
bereav
period
preliminari
result
patient
famili
report
posit
patient
experi
improv
prefer
place
death
patient
feel
abandon
hand
anoth
servic
famili
end
life
experi
improv
due
patient
famili
well
known
palli
homecar
staff
respiratori
nurs
direct
admiss
inpati
palli
care
servic
prevent
visit
emerg
prevent
hospit
admiss
final
year
life
improv
qualiti
life
reduct
emerg
call
ambul
servic
due
breathless
anxieti
conclus
share
model
earli
referr
access
palli
care
markedli
improv
qualiti
servic
patient
advanc
nonmalign
lung
diseas
train
requir
support
palli
homecar
nurs
deliv
care
patient
nonmalign
diseas
equal
chronic
diseas
nurs
support
deliv
palli
care
approach
ical
util
emerg
commerci
equip
prognost
valu
perform
preschool
mbw
defin
age
year
remain
unclear
previous
shown
associ
higher
preschool
lung
clearanc
index
lci
valu
greater
medic
use
incid
bacteri
isol
within
clinic
studi
aim
explor
associ
preschool
lci
valu
later
spirometri
well
establish
clinic
tool
older
cf
subject
method
current
spirometri
valu
fev
fev
collat
origin
preschool
children
mbw
perform
mean
sd
age
rang
yr
median
rang
lci
spirometri
result
express
zscore
gli
refer
equat
abnorm
preschool
lci
defin
base
recent
publish
preschool
healthi
control
data
use
ident
equip
test
protocol
uln
lci
result
technic
accept
spirometri
data
avail
one
move
state
one
autism
mean
sd
rang
age
year
year
origin
mbw
test
time
point
later
spirometri
z
score
result
children
sma
ii
median
age
month
includ
median
fvc
predict
z
score
rr
zscore
xr
zscore
snip
zscore
lci
median
iqr
rem
relat
apneahypopnea
index
rahi
high
children
sma
ii
requir
longterm
nocturn
niv
initi
median
age
month
acut
respiratori
ill
children
older
vs
month
significantli
wors
fvcz
score
vs
p
rahi
vs
lci
vs
snip
zscore
vs
predictor
niv
need
analys
use
logist
regress
model
prospect
arm
complet
conclus
children
sma
ii
need
nocturn
ventilatori
support
begin
earli
childhood
fvc
may
predictor
fot
snip
lci
derang
may
help
predict
earli
respiratori
insuffici
particularli
earli
year
school
human
scienc
physiolog
univers
western
australia
perth
australia
centr
neonat
research
educ
school
paediatr
child
health
univers
western
australia
perth
australia
introductionaim
chorioamnion
associ
preterm
birth
develop
airway
diseas
later
life
chorioamnion
promot
lung
inflamm
effect
airway
smooth
muscl
asm
function
unknown
postnat
steroid
given
preterm
infant
sever
lung
diseas
may
benefici
effect
airway
develop
studi
examin
separ
combin
effect
chorioamnion
postnat
steroid
asm
contract
preterm
ovin
model
method
chorioamnion
induc
ultrasoundguid
intraamniot
ia
inject
lipopolysaccharid
lp
timem
ewe
gestat
postnat
lpsexpos
lamb
receiv
intraven
lowdos
dexamethason
lpsdex
salin
lpssal
commenc
within
h
birth
postnat
control
receiv
ia
salin
gestat
daili
intraven
lowdos
dexamethason
saldex
salin
salsal
postnat
lamb
deliv
via
caesarean
section
gestat
receiv
respiratori
support
requir
euthanis
ie
postconcept
age
fifth
group
fetal
control
lamb
euthanis
immedi
gestat
matur
control
bronchial
ring
studi
organ
bath
chamber
isometr
forc
product
acetylcholin
measur
doserespons
curv
construct
determin
maxim
respons
slope
sensit
asm
thick
determin
histolog
masson
trichrom
result
maxim
respons
slope
sensit
similar
matur
postnat
placebo
control
indic
asm
contract
unaffect
preterm
deliveri
maxim
respons
increas
ia
lp
administr
p
significantli
affect
postnat
dexamethason
doserespons
slope
reduc
postnat
dexamethason
p
lpsexpos
lamb
asm
thick
lower
anim
treat
postnat
dexamethason
irrespect
prior
exposur
lp
p
asthma
efficaci
limit
adrenoceptor
desensitis
free
fatti
acid
receptor
express
mous
human
lung
mizuta
et
al
ajp
lung
agonist
caus
relax
mous
airway
greater
efficaci
salbutamol
bourk
et
al
ajrcmb
aim
compar
bronchodil
salbutamol
agonist
agonist
condit
desensitis
test
potenti
desensitis
assess
ffar
express
mous
airway
model
chronic
allerg
airway
diseas
human
airway
subject
without
asthma
method
precis
cut
lung
slice
prepar
male
balbc
mice
airway
relax
salbutamol
compar
overnight
incub
salbutamol
vehicl
immunohistochemistri
ffar
perform
lung
section
salin
control
c
ovalbumin
ova
sensitis
mice
airway
biopsi
nonasthmat
na
asthmat
subject
result
salbutamol
ffar
agonist
relax
airway
precontract
methacholin
relax
salbutamol
overnight
incub
salbutamol
reduc
subsequ
relax
salbutamol
p
cf
control
respect
incub
affect
salbutamolor
relax
resepect
express
similar
c
found
singl
bout
moderateintens
exercis
decreas
exhal
nitric
oxid
physic
inact
physic
activ
adult
asthma
aim
studi
examin
acut
effect
exercis
intens
airway
inflamm
adult
asthma
examin
whether
differ
usual
exercis
level
method
randomis
control
trial
adult
asthma
randomis
complet
either
minut
moderateintens
exercis
hrmax
cycl
ergomet
minut
vigorousintens
exercis
hrmax
cycl
ergomet
minut
rest
sputum
cell
count
obtain
day
prior
hourspost
exerciserest
result
sputum
eosinophil
count
lower
follow
moderateintens
exercis
ml
versu
rest
ml
howev
sputum
eosinophil
count
chang
follow
vigorousintens
exercis
ml
versu
rest
particip
report
perform
exercis
caus
breathless
sweat
per
week
signific
decreas
sputum
eosinophil
count
vs
ml
sputum
eosinophil
vs
follow
moderateintens
exercis
compar
rest
particip
becam
breathless
sweati
exercis
chang
sputum
eosinophil
count
sputum
eosinophil
follow
exercis
challeng
conclus
studi
demonstr
acut
bout
moderateintens
vigorousintens
exercis
reduc
sputum
eosinophil
adult
asthma
chang
evid
physic
inact
particip
suggest
regular
physic
activ
may
protect
airway
inflamm
method
random
doubleblind
placeboor
activecontrol
studi
phase
phase
tc
conduct
cf
patient
genotyp
latter
week
teziva
pretreat
primari
object
safeti
toler
efficaci
pharmacodynam
effect
assess
absolut
chang
ppfev
sweat
chlorid
baselin
respect
result
baselin
characterist
balanc
ng
tc
regimen
well
toler
advers
event
ae
mild
moder
ae
lead
discontinu
includ
increas
alanin
aminotransferaseaspart
aminotransferas
tc
pneumonia
tc
respir
abnormalsputum
increas
placebo
week
signific
improv
baselin
ppfev
percentag
point
seen
ng
tc
regimen
patient
signific
improv
baselin
percentag
point
seen
tc
top
teziva
patient
vs
teziva
baselin
signific
reduct
baselin
sweat
chlorid
also
seen
tc
regimen
vs
placebo
teziva
alon
conclus
first
demonstr
substanti
improv
ng
tc
regimen
patient
cf
genotyp
previou
cftr
modul
fail
patient
cf
genotyp
ongo
studi
guid
develop
tc
regimen
introduct
cystic
fibrosi
cf
result
insulin
defici
birth
progress
cystic
fibrosisrel
diabet
cfrd
cfrd
signific
impact
lung
function
respiratori
infect
nutrit
lead
increas
mortal
howev
preval
earli
hyperglycaemia
impact
respiratori
tract
infect
young
children
cf
remain
unknown
aim
determin
preval
hyperglycaemia
children
cf
use
continu
glucos
monitor
cgm
correl
hyperglycemia
cgm
presenc
cf
pathogen
neutrophil
percentag
routin
bronchoalveolar
lavag
bal
method
singlecentr
studi
children
cf
cgm
devic
cgm
medtron
minim
insert
clinic
well
routin
bronchoscopyb
worn
day
cgm
outcom
includ
peak
glucos
time
spent
area
curv
auc
bal
sampl
cultur
cell
count
differenti
determin
ttest
regress
analysi
undertaken
examin
relationship
hyperglycaemia
presenc
cf
pathogen
neutrophil
percentag
bal
result
children
femal
cgm
perform
neutrophil
percentag
result
avail
median
age
year
rang
day
glucos
meana
sd
diabet
rang
glucos
level
particip
posit
cultur
spent
greater
period
time
cgm
mean
time
compar
cultur
neg
particip
greater
glucos
auc
posit
correl
peak
glucos
r
auc
r
p
neutrophil
burden
lavag
conclus
young
children
cf
demonstr
diabet
rang
hyperglycaemia
cgm
cf
pathogen
like
present
glucos
abnorm
sever
signific
correl
neutrophil
count
hyperglycemia
demonstr
research
underway
determin
whether
abnorm
cgm
cohort
impact
nutrit
pulmonari
inflamm
lung
function
introductionaim
imag
medic
beamlin
imbl
australian
synchrotron
design
world
widest
synchrotron
xray
beam
facilit
clinic
imag
therapeut
applic
human
well
imag
larg
anim
model
group
current
interest
imag
airway
newlydevelop
cf
anim
model
display
humanlik
lung
diseas
cf
pig
hypothesis
abil
lung
clear
inhal
particul
mucociliari
transit
mct
use
outcom
measur
assess
effect
cf
airway
therapi
studi
extend
find
ex
vivo
sheep
pig
tracheal
tissu
studi
previous
perform
imbl
design
determin
whether
design
imbl
suitabl
imag
pig
airway
method
small
sampl
diamet
high
refract
index
hri
glass
bead
marker
particl
deliv
tracheal
airway
surfac
eight
live
piglet
autom
analysi
algorithm
use
track
quantifi
depositedparticl
motion
includ
respons
aerosol
deliveri
hyperton
salin
highresolut
comput
tomograph
ct
wholeanim
postmortem
scan
one
pig
also
perform
verifi
largesampl
ct
capabl
imbl
result
mct
track
particl
visibl
anim
autom
mct
track
algorithm
abl
identifi
track
particl
ct
whole
anim
success
acquir
visualis
success
made
ct
dataset
due
unexpect
imbl
technic
equip
issu
shutter
xray
bean
sometim
poorli
control
result
high
radiat
dose
anim
conclus
studi
demonstr
imbl
suitabl
larg
anim
tracheal
mct
imag
ct
radiat
dose
must
care
reliabl
control
futur
nonrecoveri
studi
enabl
estim
minimum
achiev
dose
experi
design
medic
imag
st
vincent
hospit
fitzroy
australia
medicin
univers
tasmania
hobart
australia
royal
princ
alfr
hospit
camperdown
australia
introductionaim
idiopath
pulmonari
fibrosi
ipf
progress
scar
lung
diseas
unknown
caus
limit
treatment
median
surviv
year
aim
identifi
potenti
occup
environment
exposur
associ
develop
ipf
australia
method
case
recruit
australian
ipf
registri
patient
complet
questionnair
demograph
smoke
famili
histori
environment
occup
exposur
medic
histori
clinic
radiolog
histopatholog
data
review
multidisciplinari
panel
popul
base
control
recruit
random
digit
diall
frequenc
match
age
sex
state
interview
collect
compar
data
multivari
logist
regress
use
assess
associ
ipf
odd
ratio
confid
interv
ci
adjust
age
sex
smoke
result
data
case
assess
multidisciplinari
discuss
definit
probabl
possibl
ipf
control
meanaesd
age
case
control
year
case
control
male
current
past
tobacco
smoke
associ
increas
risk
ipf
ci
marijuana
use
appear
protect
famili
histori
pulmonari
fibrosi
associ
fold
increas
risk
ipf
domest
environment
exposur
associ
increas
risk
pet
bird
stand
water
appear
protect
respect
selfreport
occup
exposur
asbesto
associ
increas
risk
silica
appear
protect
selfreport
occup
exposur
gase
fume
chemic
dust
associ
ipf
conclus
preliminari
find
suggest
burden
ipf
could
reduc
continu
tobacco
control
measur
prevent
ongo
exposur
asbesto
detail
assess
occup
exposur
undertaken
use
finnish
job
exposur
matrix
allianc
research
exercis
nutrit
activ
arena
sansom
institut
school
health
scienc
univers
south
australia
adelaid
australia
school
health
scienc
sansom
institut
health
research
univers
south
australia
adelaid
australia
introductionaim
longitudin
surveil
firefight
lung
function
highli
valuabl
especi
consid
util
determin
chang
function
follow
disastr
exposur
studi
investig
longterm
rate
chang
lung
function
paramet
firefight
howev
produc
mix
find
aim
determin
rate
chang
fev
fvc
contemporari
cohort
profession
south
australian
metropolitan
fire
servic
samf
firefight
method
spirometri
conduct
stage
avail
consent
fulltim
firefight
staff
accord
atser
criteria
use
viasi
masterscreen
spirometri
system
examin
serial
fev
fvc
measur
determin
averag
rate
chang
use
linear
mix
effect
model
result
particip
stage
data
collect
rang
approxim
data
individu
male
firefight
contribut
averag
ae
rang
measur
includ
analysi
fifti
per
cent
includ
firefight
least
three
measur
preliminari
analys
show
proport
firefight
lower
limit
normal
lln
baselin
fev
fvc
fev
fvc
longitudin
fev
adjust
baselin
age
height
declin
ci
mlyr
fvc
declin
ci
mlyr
samf
firefight
observ
studi
show
normal
level
fev
fvc
baselin
unsurpris
given
select
part
base
physic
fit
earli
result
indic
cohort
normal
rate
chang
fev
fvc
suggest
lung
function
remain
rel
unaffect
occup
indigen
children
young
adult
age
year
seven
queensland
commun
questionnair
medic
chart
review
identifi
healthi
particip
respiratori
andor
atop
ill
ever
result
accept
feno
measur
achiev
children
year
adult
year
particip
histori
respiratori
andor
atopi
condit
exclud
result
healthi
cohort
children
adult
geometr
mean
feno
result
children
adult
respect
tabl
summaris
distribut
healthi
feno
result
ethnic
group
accord
current
cutoff
rang
conclus
although
major
particip
feno
result
within
agerespect
normal
rang
found
proport
healthi
particip
elev
feno
result
group
greatest
proport
elev
result
seen
torr
strait
island
children
adult
aboriginaltorr
strait
island
children
suggest
recommend
cutoff
rang
may
appropri
group
investig
still
need
aim
analys
efficaci
ldct
detect
lung
cancer
asbestosexpos
popul
period
method
asbesto
review
program
base
sir
charl
gairdner
hospit
began
perform
annual
ldct
screen
asbestosexpos
popul
asbesto
relat
lung
diseas
lung
cancer
popul
wittenoom
miner
resid
individu
month
cumul
full
time
exposur
particip
prone
ldct
scan
annual
health
questionnair
includ
smoke
statu
spirometri
ga
transfer
result
ldct
scan
perform
individu
median
age
year
iqr
male
eversmok
lung
cancer
diagnos
particip
cohort
preoper
stage
b
underw
treatment
cur
intent
underw
noncur
chemoradi
lung
cancer
preval
incid
individu
see
tabl
one
particip
die
month
surgeri
found
diseas
oper
particip
treat
cur
reoccurr
date
mesothelioma
diagnos
individu
asbestosi
present
arp
popul
pleural
plaqu
confirm
signific
asbesto
exposur
median
radiat
exposur
per
ldct
iqr
conclus
care
control
ldct
screen
program
effect
diagnos
treat
earlystag
lung
cancer
popul
occup
exposur
asbesto
account
assess
risk
lung
cancer
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
part
per
billion
increas
exposur
associ
reduc
l
co
doserespons
manner
pfortrend
compar
lowest
quartil
exposur
reduct
l
co
equival
predict
highest
quartil
ci
independ
smoke
significantli
lower
current
asthma
p
interact
trend
reduc
tlc
reduct
postbd
fvc
nonand
past
current
smoker
expos
highest
quartil
nonsmok
pred
p
interact
statist
signific
relationship
postbd
fev
fvc
fef
ga
trap
rvtlc
provid
evid
moder
advers
associ
exposur
l
co
rel
low
pollut
level
vari
current
asthma
statu
nonobstruct
featur
favour
lung
parenchym
process
although
coexist
small
airway
narrow
may
mask
reduc
fvc
level
new
knowledg
support
environment
polici
reduc
level
low
feasibl
introductionaim
acceler
adult
lung
function
declin
major
pathway
chronic
obstruct
pulmonari
diseas
sought
investig
associ
interact
life
span
factor
lung
function
declin
middl
age
method
postbronchodil
lung
function
measur
year
particip
tasmanian
longitudin
health
studi
use
multivari
linear
regress
investig
associ
factor
adulthood
current
asthma
smoke
atopi
bmi
bmi
chang
occup
exposur
traffic
relat
air
pollut
childhood
pneumonia
asthma
parent
asthma
parent
smoke
glutathion
stransferas
gene
polymorph
rate
lung
function
declin
year
interact
factor
also
investig
result
current
asthma
ci
mlyear
current
smoke
mlyear
atopi
mlyear
year
lifetim
occup
exposur
vapourgasdustfum
mlyear
increas
bmi
followup
period
mlyear
per
kgm
increas
independ
associ
acceler
fev
declin
control
age
height
sex
socioeconom
statu
lung
function
baselin
year
current
smoke
ml
year
bmi
chang
mlyear
per
kgm
increas
associ
greater
fvc
declin
polymorph
modifi
effect
occup
exposur
heavi
matern
smoke
childhood
modifi
effect
person
smoke
fev
fvc
declin
effect
occup
exposur
signific
carrier
null
genotyp
effect
person
smoke
augment
also
expos
matern
smoke
conclus
lung
function
declin
middleag
sampl
predominantli
influenc
adult
factor
exposur
matern
smoke
childhood
genet
suscept
may
predispos
peopl
suscept
adulthood
exposur
introductionaim
person
vapor
electroniccigarett
aerosolis
liquid
ejuic
produc
aerosol
inhal
regul
ejuic
ingredi
tensofthousand
differ
flavour
nicotin
concentr
excipi
blend
avail
thousand
supplier
furthermor
mani
ingredi
approv
food
addit
inhal
toxicolog
data
may
unavail
aim
test
physicochem
properti
rang
ejuic
aerosol
identifi
potenti
toxic
substanc
ii
see
whether
ingredi
match
label
method
ejuic
obtain
australian
us
retail
ejuic
chemistri
analys
via
gcm
aerosol
gener
use
custommad
devic
base
innokin
vapor
innokin
cartom
set
aerosol
collect
minut
use
appropri
filter
collect
tube
assess
level
carbonyl
volatil
organ
polycyclicaromat
nicotin
particul
matter
metal
aerosol
mass
size
distribut
measur
use
optic
particl
spectromet
result
differ
chemic
detect
ejuic
includ
known
respiratori
irrit
nicotin
detect
appar
nicotinefre
juic
seven
metal
identifi
aerosol
includ
titanium
chromium
nickel
also
identifi
carbonyl
howev
formaldehyd
acetaldehyd
aceton
common
sixteen
volatil
organ
identifi
solvent
hexan
ethanol
ubiquit
sampl
polycycl
aromat
detect
aerosol
contain
particul
matter
huge
vari
level
particl
size
distribut
also
vari
consider
appar
base
excipi
mixtur
physicochem
properti
ejuic
aerosol
vari
wide
henc
potenti
impact
health
also
like
vari
importantli
nicotin
found
mani
nicotinefre
juic
implic
addict
introductionaim
copd
incur
progress
ill
associ
signific
morbid
mortal
accur
determin
prognosi
sever
copd
wellrecognis
challeng
diagnos
activ
die
aim
audit
use
diagnost
test
recognis
activ
die
establish
goal
care
goc
palliat
copd
patient
die
hospit
method
gener
practic
blockrandomis
icg
interdisciplinari
care
group
ucg
usual
care
group
patient
particip
spirometryconfirm
copd
ucg
practic
receiv
routin
care
gp
quitlin
referr
appropri
icg
particip
receiv
radic
model
care
coordin
research
assist
gp
staff
clinic
model
compris
individualis
smoke
cessat
support
home
medicin
review
hmr
consult
pharmacist
homebas
pulmonari
rehabilit
specif
train
physiotherapist
primari
endpoint
chang
health
relat
qualiti
life
hrqol
measur
st
georg
respiratori
questionnair
sgrq
month
baselin
outcom
includ
chang
lung
function
dyspnoea
copd
assess
test
cat
score
month
result
total
patient
copd
includ
icg
ucg
mean
aesd
age
year
male
current
smoker
mean
median
baselin
sgrq
cat
mmrc
score
total
icg
particip
receiv
hmr
complet
homebas
pulmonari
rehabilit
receiv
compon
six
month
followup
complet
month
followup
progress
complet
februari
conclus
interdisciplinari
model
care
copd
develop
implement
evalu
gener
practic
hmr
homebas
pulmonari
rehabilit
moder
accept
intervent
gp
patient
grantinkind
support
nhmrc
lung
foundat
australia
boehring
ingelheim
eastern
melbourn
phn
cyril
tonkin
scholarship
conflict
interest
fund
receiv
boehring
ingelheim
boehring
ingelheim
involv
project
discuss
plan
progress
review
involv
design
intervent
program
contribut
decis
regard
data
analysi
dissemin
find
introduct
lfa
undertook
survey
gain
insight
key
issu
face
consum
carer
understand
lfa
meetsor
better
meettheir
need
method
survey
distribut
via
email
post
consum
lung
diseas
subscrib
lfa
network
result
survey
complet
repres
respons
rate
approxim
femal
age
year
lung
diseas
carer
respond
indic
see
famili
friend
less
often
feel
isol
societi
thing
love
less
often
lung
diseas
ask
specif
felt
time
diagnosi
felt
less
deserv
help
peopl
medic
condit
felt
shame
guilt
fear
discrimin
felt
stigmatis
view
lung
diseas
selfinflict
smokingrel
felt
support
need
deal
diagnosi
suggest
receiv
addit
lfa
support
respons
highlight
need
psychosoci
support
telephon
onlin
facetofac
connect
lfa
consum
well
need
addit
educ
seminar
webinar
inform
specif
diseas
treatment
research
conclus
peopl
impact
lung
diseas
face
mani
challeng
survey
detail
effect
commun
social
interact
feel
isol
less
contact
love
one
highlight
also
demonstr
shame
stigma
guilt
peopl
may
experi
diagnos
lung
diseas
method
cultur
bronchial
aec
baec
line
control
copd
donor
differenti
airliquid
interfac
ali
expos
cigarett
smokeextract
cse
nthi
marker
xenophag
flux
intracellular
nthi
assess
use
western
analysi
immunofluoresc
transmiss
electron
microscopi
tem
result
aec
expos
cse
exhibit
block
autophag
flux
downregul
xenophagymicrobi
adapt
protein
immunofluoresc
analysi
resolv
intracellular
nthi
within
aec
expos
cse
proxim
autophag
apparatu
marker
importantli
control
ali
cultur
expos
nthi
contain
detect
infect
evid
normal
autophag
activ
wherea
copdderiv
baec
contain
multipl
infect
particl
remain
intact
within
autophagosomelik
vesicl
tem
analysi
demonstr
expuls
autophagosomelik
vesicl
conclus
nthi
abl
avoid
xenophag
degrad
aec
expos
cse
cultur
copdderiv
aec
may
usurp
defect
autophag
apparatu
mode
persist
extracellular
propag
henc
mode
therapeut
intervent
restor
normal
xenophag
activ
aec
signific
util
improv
clearanc
intracellular
nthi
infect
therebi
decreas
influenc
damag
pathogen
airway
afflict
copd
grant
support
thorac
societi
australia
new
zealand
astrazeneca
nthi
consider
autophag
activ
evidenc
dark
electron
dens
region
within
vesicular
structur
convers
nthi
readili
evid
aec
deriv
copd
donor
close
proxim
similar
vesicular
structur
respirolog
introductionaim
influenza
signific
global
burden
million
case
per
year
fatal
thu
urgent
need
new
therapeut
toll
like
receptor
pattern
recognit
receptor
drive
power
antivir
signal
pathway
help
clear
viru
infect
aim
present
studi
determin
effect
agonist
imiquimod
morbid
lung
inflamm
oxid
stress
antibodi
product
caus
influenza
viru
iav
infect
mice
method
salin
imiquimod
deliv
intranas
anaesthetis
male
mice
one
day
prior
infect
low
pfumous
high
dose
pfumous
mous
adapt
hong
kong
viru
strain
everyday
thereaft
mice
cull
day
postinfect
analysi
bronchoalveolar
lavag
bal
perform
assess
airway
inflamm
inflammatori
cell
oxid
burst
enhanc
chemiluminesc
addit
bal
fluid
serum
use
determin
antibodi
titr
lung
harvest
use
assess
inflamm
h
e
stain
proinflammatori
cytokin
gene
express
qpcr
bodyweight
record
daili
experiment
process
result
imiquimod
significantli
suppress
bodi
weight
loss
caus
iav
infect
maximum
reduct
start
day
pfumous
p
post
infect
imiquimod
treatment
caus
signific
reduct
airway
peribronchi
inflamm
balf
neutrophil
popul
pfumous
p
effect
macrophag
lymphocyt
popul
oxid
burst
mrna
express
supress
p
p
respect
whilst
mrna
express
unaffect
day
data
show
modest
signific
increas
ige
igm
p
balf
follow
imiquimod
treatment
compar
control
chang
antibodi
titr
within
serum
find
highlight
potenti
imiquimod
therapeut
option
treatment
influenza
diseas
lack
understand
host
immun
respiratori
infect
cov
studi
characteris
innat
immun
respons
differenti
primari
bronchial
epitheli
cell
pbec
infect
relat
lessvirul
method
human
pbec
grown
air
liquid
interfac
ali
differenti
observ
day
infect
multipl
infect
moi
hour
day
supernat
rna
collect
measur
proinflammatoryand
antiviralcytokin
viral
replic
use
microarray
gene
express
profil
infect
analys
cell
transduc
overexpress
interferoninduc
transmembran
protein
ifitm
infect
viral
replic
measur
hour
postinfect
result
demonstr
differ
viral
replic
kinet
replic
earlier
effici
peak
hour
associ
delay
robust
activ
innat
host
respons
induct
type
iii
interferon
ifn
stimul
gene
contrast
replic
peak
hour
attenu
level
microarray
data
also
identifi
ifitm
protein
upregul
infect
cell
overexpress
ifitm
replic
suppress
ifitm
clone
display
similar
replic
kinet
control
replic
unhind
overexpress
ifitm
protein
conclus
studi
demonstr
replic
differenti
pbec
induc
diverg
innat
immun
respons
potenti
link
differ
replic
kinet
understand
hostviru
interact
less
virul
coronavirus
give
insight
pathogen
mechan
underpin
sarscov
merscovinduc
respiratori
diseas
result
acut
model
tgfb
overexpress
day
prior
iav
infect
mice
experienc
sever
bronchiti
pneumonia
increas
inflammatori
cell
infiltr
enhanc
cytokin
chemokin
product
bronchoalveolar
lavag
bal
fluid
compar
mice
normal
tgfb
level
mice
also
demonstr
suppress
innat
immun
respons
associ
enhanc
viral
titr
chronic
model
tgfb
overexpress
week
result
thicken
respiratori
bronchiol
epithelium
surround
smooth
muscl
emphysemat
appear
within
airspac
resembl
phenotyp
chang
characterist
asthma
copd
preliminari
result
model
demonstr
iav
infect
sever
compar
mice
normal
tgfb
level
conclus
transgen
mous
model
provid
us
uniqu
tool
evalu
direct
effect
tgfb
viral
infect
context
chronic
inflammatori
lung
diseas
investig
potenti
therapeut
strategi
combat
viralinduc
diseas
exacerb
aim
primari
sourc
airflow
limit
copd
small
airway
sa
fibrosi
obliter
previous
show
epitheli
mesenchym
transit
emt
activ
process
small
airway
contribut
fibrot
pathogenesi
myofibroblast
highli
activ
fibrot
cell
excess
secret
extracellular
matrix
ecm
explor
consequ
sa
myofibroblast
prolifer
relat
physiolog
outcom
airway
remodel
smoker
copd
patient
method
sa
lung
resect
nonsmok
control
nc
normal
lung
function
smoker
nlf
copd
current
cs
exsmok
es
stain
antihuman
fibronectin
cell
enumer
reticular
basement
membran
rbm
lamina
propria
lp
adventitia
repres
per
mm
rbm
mm
respect
area
survey
fibronectin
repres
percentag
chang
measur
includ
subepitheli
lp
adventitia
thick
measur
use
imageproplu
observ
gener
increas
subepitheli
lp
adventitia
thick
patholog
group
compar
nc
similar
increas
myofibroblast
observ
subepitheli
rbm
lp
adventitia
patholog
group
compar
nc
though
chang
promin
higher
lp
increas
myofibroblast
popul
lp
strongli
associ
decreas
lung
function
increas
ecm
protein
fibronectin
deposit
lp
final
observ
emt
marker
express
epitheli
basal
cell
rbm
correl
increas
sa
myofibroblast
airway
thick
conclus
first
report
systemat
character
myofibroblast
copd
base
local
statist
correl
lung
function
increas
myofibroblast
popul
also
directli
relat
patholog
chang
ecm
protein
drive
chang
like
emt
activ
basal
epitheli
cell
introductionaim
skelet
muscl
wast
major
comorbid
copd
power
predictor
mortal
current
therapeut
strategi
aim
increas
muscl
mass
augment
protein
synthesi
reduc
protein
degrad
muscl
mass
also
increas
activ
satellit
cell
play
pivot
role
skelet
muscl
regener
howev
role
satellit
cell
copd
fulli
understood
thu
explor
whether
muscl
regener
respons
injur
tibiali
anterior
ta
muscl
impair
mice
expos
cigarett
smoke
cs
method
male
balbc
mice
expos
room
air
sham
cs
gener
cigarettesday
daysweek
week
week
cs
exposur
right
ta
muscl
injur
inject
barium
chlorid
bacl
mice
expos
cs
anoth
day
time
contractil
properti
right
ta
muscl
measur
mice
cull
uninjur
left
ta
injur
right
ta
muscl
dissect
weigh
use
examin
express
gene
associ
muscl
regener
eg
pax
histolog
assess
muscl
injuri
result
bacl
induc
injuri
significantli
decreas
weight
ta
muscl
day
post
injuri
exacerb
csexpos
mice
p
bacl
also
caus
signific
muscl
injuri
demonstr
central
locat
nuclei
alter
tissu
architectur
assess
day
post
injuri
howev
muscl
injuri
even
greater
csexpos
mice
compar
injur
sham
mice
p
injur
ta
muscl
csexpos
mice
least
twofold
increas
pax
mrna
express
compar
injur
ta
muscl
shamexpos
mice
day
post
injuri
p
moreov
ta
muscl
contractil
function
significantli
impair
injur
csexpos
mice
compar
injur
shamexpos
mice
p
conclus
skelet
muscl
regener
function
impair
experiment
copd
introductionaim
airway
distens
reduc
patient
copd
transform
growth
factor
alpha
increas
serum
copd
patient
produc
airway
remodel
mous
model
hypothesis
overexpress
reduc
airway
distens
aim
determin
effect
regulatori
gene
earli
growth
respons
one
airway
thick
distens
method
condit
express
airway
transgen
mice
clara
cell
secretori
proteinrtta
teto
induc
doxycyclin
dox
mice
homozyg
heterozyg
week
age
mice
fed
dox
chow
control
diet
week
anaesthetis
mechan
ventil
lung
function
measur
use
low
frequenc
forc
oscil
airway
conduct
g
measur
transrespiratori
pressur
g
g
distens
calcul
chang
conduct
g
g
lung
fix
morphometri
stereolog
result
doxf
mice
increas
thick
airway
epithelium
inner
outer
wall
airway
smooth
muscl
layer
increas
thick
epithelium
inner
wall
greater
mice
chang
affect
genotyp
doxf
mice
reduc
airway
distens
independ
genotyp
conclus
increas
express
within
airway
wall
associ
increas
wall
thick
reduc
airway
distens
effect
larg
unaffect
partial
modif
gene
find
suggest
signal
may
contribut
airflow
limit
copd
reduc
airway
distens
gold
coast
hospit
health
servic
southport
queensland
australia
school
medicin
griffith
univers
southport
queensland
australia
introductionaim
copd
patient
peripher
eosinophilia
may
increas
frequenc
copd
exacerb
respond
better
oral
corticosteroid
reduc
mortal
peripher
eosinophilia
copd
patient
eosinophil
count
white
blood
cell
count
preval
rang
knowledg
littl
epidemiolog
data
australian
copd
patient
concern
peripher
eosinophilia
preval
associ
rehospitalis
rate
steroid
respons
diseas
mortal
rate
literatur
gap
mind
record
patient
present
copd
exacerb
audit
retrospect
determin
preval
peripher
eosinophilia
australian
popul
method
consecut
patient
spirometri
confirm
copd
admit
institut
copd
exacerb
period
juli
decemb
consid
studi
patient
record
subsequ
follow
june
variabl
record
white
blood
cell
count
absolut
rel
eosinophil
count
readmiss
rate
decompens
type
respiratori
failur
rate
noninvas
ventil
initi
rate
intens
care
admiss
rate
mortal
rate
result
patient
includ
analysi
peripher
eosinophilia
use
pearson
coeffici
appear
statist
signific
correl
increas
peripher
eosinophil
count
increas
number
readmiss
decompens
type
respiratori
failur
noninvas
ventil
initi
rate
intens
care
admiss
rate
mortal
rate
twosampl
ttest
equal
mean
compar
peripher
eosinophilia
without
also
keep
statist
signific
differ
readmiss
rate
patient
similar
oversea
cohort
congruenc
find
previou
oversea
studi
gold
coast
patient
eosinophilia
prone
readmiss
increas
type
respiratori
failur
noninvas
ventil
intens
care
admiss
mortal
peripher
eosinophilia
use
australian
copd
patient
cohort
predict
rehospitalis
rate
futur
studi
look
prospect
evalu
effect
inhal
corticosteroid
readmiss
rate
patient
peripher
eosinophilia
grant
support
none
introduct
increas
airway
smooth
muscl
asm
mass
part
overal
structur
chang
observ
copd
correl
sever
diseas
found
neg
impact
lung
function
thu
clear
unmet
clinic
need
find
new
therapi
copd
target
airway
remodel
diseas
progress
apoptosi
signalregul
kinas
ubiquit
express
activ
variou
stress
stimuli
includ
ro
lp
howev
role
airway
remodel
establish
studi
aim
determin
effect
inhibit
asm
growth
promitogen
signal
use
asm
cell
wellestablish
copd
patient
patient
greater
prolif
capac
varieti
mitogen
vitro
use
human
lung
tissu
sampl
primari
human
asm
cell
obtain
copd
patient
healthi
control
ihc
reveal
increas
express
copd
lung
compar
noncopd
lung
pretreat
human
asm
cell
highli
select
nm
oral
avail
inhibitor
result
dosedepend
reduct
mitogen
fb
pdgf
egf
ngml
hour
induc
asm
growth
measur
cyquant
assay
furthermor
sirna
prevent
mitogeninduc
human
asm
cell
growth
immunoblot
reveal
antimitogen
effect
inhibit
silenc
mediat
jnk
kinasesignal
pathway
evid
reduc
phosphoryl
downstream
effector
kinas
respect
effect
signal
conclus
collect
find
establish
antimitogen
effect
inhibit
identifi
novel
pathway
target
reduc
prevent
excess
asm
mass
copd
introductionaim
excess
procoagul
activ
drive
recurr
inflamm
fibrosi
patient
idiopath
pulmonari
fibrosi
ipf
coagul
factor
promot
heal
damag
also
exert
profibrot
cellular
effect
coagul
factor
xii
fxii
identifi
potenti
mediat
lung
fibrosi
aim
studi
defin
role
fxii
fibrogenesi
method
blood
ipf
patient
collect
repeatedli
month
compar
age
gendermatch
healthi
control
plasma
fxii
measur
immunohistochem
analysi
fxii
perform
paraffinembed
lung
tissu
ipf
patient
nondiseas
control
ndc
vitro
effect
fxii
primari
ipf
ndc
fibroblast
evalu
cytokin
product
prolifer
migrat
effect
novel
fulli
human
monoclon
antibodi
fxii
evalu
result
baselin
longitudin
level
fxii
ipf
patient
progress
diseas
elev
compar
stabl
diseas
vs
baselin
vs
longitudin
increas
ipf
compar
healthi
control
baselin
plasma
elev
ipf
patient
compar
healthi
control
pgml
ihc
analysi
reveal
signific
fxii
stain
ipf
lung
tissu
minim
stain
observ
nonfibrot
lung
tissu
activ
fxii
induc
product
enhanc
proliferationmigr
primari
lung
fibroblast
migrat
product
effect
inhibit
conclus
fxii
elev
lung
progress
ipf
patient
drive
profibrot
proinflammatori
function
fibroblast
antifxii
antibodi
inhibit
activ
abil
fxii
drive
product
lung
fibroblast
may
contribut
elev
level
seen
ipf
patient
blood
block
fxii
activ
may
novel
avenu
treat
ipf
inflammationdriven
interstiti
lung
diseas
introductionaim
lung
transplant
ltx
provid
uniqu
opportun
investig
dynam
virus
present
within
human
pulmonari
virom
transplant
recipi
within
donor
lung
aim
studi
elucid
interact
viral
speci
within
respiratori
virom
ltx
recipi
describ
impact
allograft
function
method
prospect
longitudin
studi
viral
dynam
ltx
multipl
sampl
type
collect
sampl
process
assay
use
multipl
uniplex
pcr
human
rhinoviru
hrv
respiratori
syncyti
viru
rsv
influenza
b
flu
b
parainfluenza
piv
human
metapneumoviru
clinic
outcom
analys
compar
microbi
detect
result
consecut
ltx
recruit
swab
explant
lung
posit
virus
despit
recipi
vaccin
neg
recipi
np
day
bal
show
flu
hrv
piv
donor
swab
show
influenza
hrv
donor
transmiss
flu
observ
recipi
bal
posit
sampl
virus
multipl
bal
virus
persist
week
pair
transbronchi
biopsi
viral
pcr
bal
perform
patient
show
evid
acut
cellular
reject
biopsi
grade
grade
grade
virus
detect
bal
collect
concurr
convers
patient
show
evid
cellular
reject
biopsi
viru
posit
viru
neg
analysi
use
fisher
exact
test
tail
indic
signific
correl
viral
detect
presenc
acut
cellular
reject
find
frequent
donor
transmiss
earli
acquisit
virus
particularli
influenza
support
import
respiratori
virom
surveil
ltx
direct
acut
therapi
cohort
viral
presenc
ltx
correl
acut
reject
event
introductionaim
previous
report
therapeut
effect
augment
endotheli
progenitor
cell
therapi
rat
ph
model
know
littl
direct
cell
integr
pulmonari
endothelium
follow
intraven
inject
thu
attribut
posit
physiolog
effect
cell
therapi
celltocel
commun
via
secret
factor
exosom
exo
studi
look
compar
pahepc
controlepc
protein
profil
via
mass
spectrometri
assess
capac
interact
transport
endotheli
cell
ec
method
epc
isol
cultur
pah
control
peripher
blood
cell
either
transduc
adtrackluc
untransduc
subsequ
exo
isol
exosom
isol
via
differenti
centrifug
characteris
nanosight
tem
sem
exosom
protein
profil
via
mass
spectrometri
treat
exo
gfpexo
label
use
view
exo
localis
within
target
ec
live
fix
via
confoc
microscopi
incub
ec
wash
cell
lyse
western
blot
analysi
result
exosom
posit
identifi
via
nanosight
tem
sem
protein
profil
exo
show
differenti
protein
express
pah
vs
control
protein
includ
rel
downregul
pah
exo
exosom
interact
ec
demonstr
localis
around
nucleu
cell
live
fix
ec
sampl
addit
express
significantli
increas
cell
treat
conclus
differenti
protein
express
exo
deriv
pah
compar
control
epc
shown
addit
characteris
exo
interact
ec
shown
involv
transfer
transduc
epc
ec
result
indic
potenti
role
exo
therapi
pharmaci
alfr
health
melbourn
australia
cystic
fibrosi
servic
alfr
health
melbourn
australia
lung
function
laboratori
alfr
health
melbourn
australia
introductionaim
lung
transplant
ltx
recipi
high
risk
lower
respiratori
tract
infect
lrti
secondari
immunosuppress
alter
respiratori
physiolog
make
difficult
clear
secret
inhal
mucoact
agent
alter
mucu
properti
andor
facilit
mucocilliari
clearanc
suppur
lung
diseas
howev
randomis
control
trial
rct
studi
effect
post
ltx
aim
evalu
safeti
efficaci
nebulis
dornas
alfa
compar
isoton
salin
lrti
month
post
ltx
method
inpati
adult
lrti
sputum
product
follow
bilater
sequenti
ltx
elig
assessor
blind
rct
randomis
stratifi
ltx
indic
aecyst
fibrosi
cf
particip
receiv
either
isoton
salin
dornas
alfa
nebulis
daili
month
follow
month
symptom
diari
primari
outcom
chang
lung
clearanc
index
lci
measur
multibreath
washout
secondari
outcom
includ
advers
event
spirometri
qualiti
life
readmiss
length
stay
selfreport
exacerb
baselin
month
month
result
particip
group
mean
sd
age
median
iqr
length
stay
day
sinc
ltx
ltx
indic
includ
cf
chronic
obstruct
pulmonari
diseas
signific
betweengroup
differ
lci
time
point
one
month
mean
differ
confid
interv
ci
three
month
mean
differ
ci
favour
dornas
alfa
secondari
outcom
differ
group
poor
toler
larg
variat
efficaci
pirfenidon
signific
barrier
best
patient
outcom
studi
aim
investig
whether
invitro
fibroblast
test
identifi
patient
like
benefit
pirfenidon
therapi
method
primari
lung
fibroblast
deriv
apex
base
lung
patient
ipf
patient
endstag
nonipf
ild
normal
donor
whose
lung
deem
unsuit
transplant
ndc
determin
incel
western
gapdh
level
fibroblast
measur
treatment
pirfenidon
presenceabs
transform
growth
sensit
pirfenidon
defin
decreas
level
baselin
result
treatment
pirfenidon
decreas
level
fibroblast
line
hour
figur
fibroblast
level
correl
extent
declin
respons
pirfenidon
spearman
r
patient
ipf
basal
level
fibroblast
line
correl
forc
vital
capac
fvc
predict
patient
line
deriv
spearman
r
respons
lung
fibroblast
pirfenidon
may
identifi
patient
ipf
would
benefit
said
treatment
data
suggest
patient
high
number
fibroblast
would
particular
benefit
pirfenidon
therapi
although
screen
requir
variat
level
fibroblast
may
reflect
overal
lung
fibrot
burden
correl
fvc
grant
support
none
method
epc
isol
pah
control
patient
peripher
blood
follow
characteris
expans
cell
expos
either
normoxia
co
atmoso
hypoxia
co
n
prolifer
apoptosi
assess
use
mtt
assay
flow
cytometri
protein
analysi
conduct
via
western
blot
result
epc
origin
pah
patient
prolifer
similar
rate
control
epc
normoxia
increas
ae
respect
howev
hypox
condit
prolifer
control
cell
less
pah
cell
ae
increas
respect
preliminari
data
suggest
continu
prolifer
could
due
apoptosi
resist
pah
line
assay
reveal
lower
apoptosi
level
hypoxia
exposur
pah
line
control
line
activ
smad
decreas
hypox
pah
cell
compar
control
conclus
epc
isol
peripher
blood
pah
patient
function
differ
hypox
condit
isol
control
subject
notabl
pah
epc
appear
possess
higher
resist
apoptosi
hypoxia
find
suggest
epc
could
play
role
pathogenesi
pah
contribut
aberr
prolifer
apoptosi
vascular
remodel
seen
pah
grant
support
nhmrc
rah
research
fund
exacerb
copd
associ
poor
clinic
outcom
increas
mortal
noninvas
ventil
niv
part
standard
care
poorli
toler
shown
nasal
high
flow
therapi
nhf
produc
small
reduct
transcutan
co
tension
ptco
stabl
copd
aim
compar
nhf
niv
hypercapn
copd
method
design
singleblind
randomis
control
twoway
crossov
trial
set
singl
centr
institut
new
zealand
recruit
particip
hospit
databas
particip
particip
doctor
diagnosi
copd
fev
fvc
ratio
year
smoke
histori
pack
year
pcapco
bmi
recent
exacerb
diagnosi
obstruct
sleep
apnea
obes
hypoventil
syndrom
intervent
nhf
bipap
washout
primari
outcom
measur
ptco
adjust
baselin
secondari
outcom
includ
toler
proport
particip
decreas
minut
result
ptco
ci
lower
niv
compar
nhf
proport
particip
reduct
ptco
niv
versu
nhf
versu
reduct
ptco
versu
differ
statist
signific
particip
rate
nhf
significantli
better
eas
applic
comfort
fit
willing
use
futur
stabl
copd
patient
chronic
hypercapnia
niv
result
small
reduct
ptco
compar
nhf
uncertain
clinic
signific
nhf
better
toler
nhf
may
therapeut
option
peopl
hypercapn
respiratori
failur
studi
acut
exacerb
copd
requir
method
nasopharyng
viral
pcr
sputum
cultur
creactiv
protein
chest
xray
troponin
hstni
ntermin
pro
brain
natriuret
peptid
ntprobnp
hospit
anxieti
depress
scale
had
use
construct
cumul
aetiolog
phenotyp
aecopd
use
simpl
acronym
aairway
viral
infect
bbacteri
infect
ccoinfect
ddepressionanxieti
eembol
pulmonari
ffailur
cardiac
ggener
environ
xunknown
result
aetiolog
identifi
among
uniqu
aecopd
admiss
divers
often
multifactori
aetiolog
identifi
aetiolog
baselin
lung
function
symptom
similar
across
exacerb
subtyp
infect
exacerb
associ
lower
eosinophil
p
noninfect
exacerb
lower
ph
niv
requir
higher
nonbacteri
v
bacteri
aecopd
patient
identifi
aetiolog
x
gener
frequent
exacerb
sever
acut
present
prompt
stabil
admiss
day
common
noninfect
group
viral
v
bacteri
v
coinfect
v
noninfect
subclin
cardiac
dysfunct
highli
preval
infect
noninfect
aecopd
elev
hstni
elev
ntprobnp
overal
anxietydepress
preval
aetiolog
subgroup
overal
popul
had
meansd
surviv
month
post
discharg
lower
nonvir
versu
viral
aecopd
conclus
hospit
aecopd
multidimension
multifactori
subtyp
infect
type
identifi
signific
differ
comorbid
health
care
util
laboratori
paramet
inpati
manag
post
exacerb
surviv
anxietydepress
cardiac
dysfunct
appear
preval
underdiagnos
clinic
orient
methodolog
provid
feasibl
framework
clinician
research
address
aecopd
complex
target
therapeut
intervent
grant
support
project
support
unrestrict
educ
grant
glaxosmithklin
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
introduct
treatment
agonist
may
overcom
symptom
sever
asthma
relaxin
rhrlx
receptor
agonist
exert
cardioprotect
effect
acut
heart
failur
elicit
vascular
relax
via
nitric
oxid
signal
although
previous
establish
bronchodil
efficaci
rat
airway
lam
et
al
effect
speci
potenti
enhanc
relax
yet
explor
aim
compar
bronchodil
effect
relaxin
alon
combin
adrenoceptor
agonist
isoprenalin
iso
salbutamol
sal
multipl
speci
method
tracheal
ring
bronchi
dissect
andor
precis
cut
lung
slice
pcl
contain
intrapulmonari
airway
prepar
mice
rat
guinea
pig
marmoset
human
lung
unus
donor
rhrlx
alon
combin
iso
sal
ad
airway
precontract
mch
result
rhrlx
nm
elicit
partial
relax
rat
airway
rapid
pcl
trachea
ineffect
direct
bronchodil
guinea
pig
trachea
mous
pcl
rhrlx
markedli
increas
potenc
iso
rat
pcl
without
increas
maximum
relax
sal
guinea
pig
trachea
sal
elicit
partial
relax
mous
pcl
synerg
evid
rhrlx
sal
maximum
relax
rhrlx
respons
sal
rhrlxsal
n
p
preliminari
data
show
rhrlx
elicit
relax
potenti
salmedi
relax
marmoset
human
small
airway
conclus
rhrlx
elicit
airway
relax
speci
enhanc
respons
small
larg
airway
salbutamol
across
speci
test
sinc
rhrlx
increas
potenc
salbutamol
investig
warrant
defin
therapeut
potenti
addon
asthma
therapi
human
lung
particularli
respons
current
dilat
therapi
limit
aim
determin
effect
treatment
lung
patholog
induc
highli
pathogen
strain
iav
method
male
mice
treat
daili
via
intranas
administr
dmso
control
period
mice
infect
pfu
strain
iav
pb
control
oneday
post
initi
drug
treatment
analys
day
postinfect
bronchoalveolar
lavag
bal
fluid
collect
mice
use
assess
airway
inflamm
histopatholog
analysi
lung
assess
use
h
e
stain
score
alveol
inflammatori
cell
infiltr
peribronchiolar
inflamm
superoxid
gener
bal
measur
use
enhanc
chemiluminesc
chang
cytokin
viral
mrna
express
lung
quantifi
use
realtim
qpcr
result
treatment
significantli
p
reduc
airway
inflamm
neutrophil
influx
pulmonari
inflamm
measur
degre
alveol
inflammatori
cell
infiltr
peribronchiolar
inflamm
addit
attenu
ro
gener
influenza
viral
mrna
express
mice
spatial
inhibit
endosom
compart
could
use
potenti
treatment
strategi
highli
pathogen
influenza
viru
infect
grant
support
nhmrc
australia
project
grant
id
introduct
base
limit
avail
data
amoxycillinclavulan
current
recommend
firstlin
empir
oralantibiot
treatment
nonsever
bronchiectasi
exacerb
children
azithromycin
attract
altern
long
halflif
reduc
dose
schedul
good
safeti
profil
children
test
primari
hypothesi
oral
azithromycin
noninferior
within
margin
amoxycillinclavulan
achiev
resolut
exacerb
treatment
children
bronchiectasi
method
conduct
multicentr
parallel
group
doubledummi
doubleblind
placebocontrol
rct
trial
centr
start
exacerb
children
randomis
receiv
either
amoxycillinclavulan
mgkg
bd
placebo
azithromycin
day
placebo
primari
outcom
resolut
exacerb
defin
return
baselin
studi
power
noninferior
margin
detect
resolut
rate
secondari
outcom
coughspecif
qualiti
life
pcqol
durat
exacerb
generalis
linear
model
use
calcul
rel
differ
group
result
baselin
characterist
group
amoxycillinclavulan
azithromycin
similar
resolut
compar
group
rel
risk
ci
fall
within
apriori
calcul
noninferior
margin
group
differ
durat
exacerb
day
ci
pcqol
compar
begin
exacerb
also
within
noninferior
margin
ci
conclus
azithromycin
noninferior
amoxicillinclavulan
treat
nonsever
exacerb
bronchiectasi
children
azithromycin
may
prefer
amoxicillinclavulan
select
set
eg
adher
howev
use
need
balanc
risk
treatment
failur
within
compar
amoxicillinclavulan
induc
macrolid
resist
faculti
scienc
univers
technolog
sydney
broadway
australia
introductionaim
persist
airflow
limit
pal
may
develop
older
nonsmok
asthma
howev
mechan
unknown
reduc
lung
elast
recoil
may
contribut
occur
age
may
occur
asthma
neutrophil
airway
inflamm
also
common
older
peopl
asthma
aim
determin
relationship
lung
elast
recoil
airway
inflamm
airflow
limit
hypothesis
reduc
lung
elast
recoil
neutrophil
airway
inflamm
associ
pal
older
nonsmok
asthmat
method
nonsmok
adult
asthma
treat
standardis
high
dose
inhal
corticosteroidlong
act
beta
agonist
two
month
underw
standard
lung
function
lung
elast
recoil
measur
use
oesophag
balloon
deriv
indic
loss
lung
elast
recoil
increas
k
reduc
ba
bronchoscopi
obtain
bronchoalveolar
lavag
fluid
bal
differenti
leukocyt
count
h
cytokin
measur
spearman
correl
assess
multipl
linear
regress
use
adjust
age
bmi
diseas
durat
result
nineteen
subject
male
meanaesd
age
year
asthma
durat
year
demonstr
moder
pal
meanaesd
zscore
postbronchodil
fev
fvc
fev
fvc
reduc
lung
elast
recoil
demonstr
subject
median
iqr
zscore
k
ba
fev
fvc
correl
neg
k
independ
age
bmi
diseas
durat
neutrophil
airway
inflamm
demonstr
meanaesd
neutrophil
lung
elast
recoil
correl
bal
neutrophil
count
h
cytokin
conclus
loss
lung
elast
recoil
contribut
pal
older
nonsmok
asthma
may
due
lung
tissu
chang
addit
airway
remodel
despit
lack
relationship
airway
inflamm
exploratori
studi
underli
cellular
mechan
requir
investig
altern
paradigm
lung
remodel
would
potenti
implic
prevent
pal
popul
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
method
primari
human
airway
smooth
muscl
cell
stimul
increas
concentr
nicotin
nicotin
tobacco
menthol
flavour
vaper
empir
evapour
extract
hour
mtt
assay
perform
determin
cytotox
elisa
use
assess
product
cell
isol
explant
resect
lung
tissu
copd
patient
smoker
without
copd
result
evapour
extract
cytotox
cell
cytotox
evapour
increas
aerosol
creat
higher
temperatur
evapour
extract
stimul
product
compar
unstimul
control
p
cell
peopl
copd
hyperrespons
evapour
nicotin
tobacco
flavour
evapour
stimul
significantli
greater
product
copd
cell
compar
noncopd
cell
p
product
stimul
conclus
ecigarett
potenti
contribut
patholog
copd
cytotox
caus
cell
death
ineffect
repair
seen
airway
parenchyma
copd
increas
would
contribut
proinflammatori
environ
lung
data
suggest
copd
patient
use
smoke
cessat
aid
cigarett
replac
introductionaim
mani
preschool
asthma
experi
diseas
remiss
first
year
life
may
offer
window
opportun
modifi
longterm
outcom
explor
relationship
likelihood
remiss
asthma
control
two
year
follow
diagnost
asthma
preschool
method
assembl
retrospect
birth
cohort
children
born
four
canadian
provinc
quebec
manitoba
saskatchewan
british
columbia
preschool
asthma
defin
one
hospitalis
medic
visit
within
period
asthma
children
age
less
year
remiss
assum
two
year
without
asthmarel
drug
claim
medic
visit
hospit
main
exposur
asthma
control
year
follow
diagnosi
measur
valid
pediatr
pharmacoepidemiolog
asthma
control
index
ppaci
ascertain
consecut
period
cohort
exit
occur
death
loss
medic
drug
coverag
date
last
avail
data
within
provinc
cox
regress
model
serv
estim
strength
associ
ppaci
stabil
year
post
diagnosi
remiss
adjust
potenti
confound
covari
name
demograph
eg
sex
social
assist
diseas
characterist
eg
age
atopi
therapi
eg
first
control
therapi
randomeffect
metaanalysi
aggreg
provincespecif
result
result
million
live
birth
provinc
children
less
year
met
definit
asthma
male
age
less
year
diagnosi
pool
rate
remiss
ci
personyear
poorer
asthma
control
year
follow
diagnosi
associ
increment
lower
likelihood
asthma
remiss
tabl
method
hourli
pm
fire
km
deriv
atmospher
transport
model
daili
averag
maximum
pm
assign
particip
residenti
address
fire
lung
function
evalu
use
forc
oscil
techniqu
fot
gener
z
score
resist
rr
two
measur
reactanc
follow
reactanc
frequenc
xr
area
reactanc
curv
ax
use
generalis
linear
model
adjust
matern
smoke
pregnanc
matern
stress
fire
assess
associ
pm
exposur
lung
function
conclus
first
report
describ
ct
lung
find
cftr
correctorpotenti
therapi
patient
year
age
homozyg
exploratori
analysi
bronchiectasi
air
trap
score
improv
patient
treat
lumiva
worsen
placebo
group
data
suggest
lumiva
may
reduc
cf
diseaserel
chang
lung
morpholog
support
need
studi
introduct
low
attenu
region
lar
chest
ct
import
compon
endstag
lung
diseas
reflect
small
airway
diseas
cystic
fibrosi
cf
howev
extent
lar
revers
young
children
unknown
aim
assess
localis
chang
lar
distribut
time
relat
cflung
diseas
outcom
hypothesis
proport
lar
irrevers
young
children
cf
indic
clinic
sever
method
children
arest
cf
cohort
contribut
ct
scan
clinic
data
annual
consecut
visit
localis
chang
lar
distribut
assess
use
specialis
imag
analysi
softwar
match
ct
lung
imag
two
time
point
measur
lung
volum
proport
new
larnew
revers
larrevers
stabl
larstabl
lar
linear
mix
effect
model
adjust
age
multipl
visit
assess
differ
lar
outcom
associ
clinic
predictor
includ
age
pancreat
suffici
bronchiectasi
extent
determin
pragmacf
method
pulmonari
inflamm
infect
measur
bronchoalveolar
lavag
introductionaim
studi
show
signific
proport
infant
cystic
fibrosi
cf
diminish
lung
function
within
first
year
life
howev
unknown
whether
lung
function
test
infanc
potenti
predict
wors
prognosi
determin
infant
like
benefit
treatment
earli
life
studi
aim
investig
whether
diminish
lung
function
detect
infant
diagnos
follow
newborn
screen
associ
wors
lung
function
remeasur
schoolag
method
lung
function
assess
individu
cf
diagnos
newborn
screen
year
school
age
year
rais
volum
rapid
thoracoabdomin
compress
rvrtc
techniqu
multipl
breath
washout
mbw
test
perform
infanc
spirometri
mbw
perform
schoolag
mixedeffect
model
use
determin
outcom
rvrtc
forc
expiratori
volum
second
fev
fvc
well
lung
clearanc
index
lci
mbw
test
associ
fev
fvc
fev
fvc
measur
spirometri
lci
schoolag
result
age
heightadjust
fev
fvc
heightadjust
lci
infanc
associ
zfev
zfvc
zfev
fvc
lci
schoolag
coeffici
confid
interv
pvalu
mixedeffect
model
shown
method
asymptomat
cf
adult
recruit
outpati
cf
clinic
quiet
room
pta
examin
frequenc
whilst
hfa
test
frequenc
hear
loss
sever
categoris
follow
slight
moder
sever
profound
record
worst
consecut
frequenc
standard
high
rang
result
total
cf
adult
mean
sd
age
year
recruit
standard
pta
detect
hear
loss
ear
show
slight
moder
sever
impair
hfa
detect
hear
loss
slight
moder
sever
profound
impair
hear
loss
standard
frequenc
exhibit
similar
wors
abnorm
high
frequenc
older
patient
show
hear
abnorm
standard
high
frequenc
conclus
preliminari
result
suggest
hfa
sensit
standard
pta
measur
potenti
hear
loss
cf
popul
comparison
result
cumul
dose
aminoglycosid
undertaken
crosssect
studi
grant
support
studi
support
novarti
grantinaid
method
inform
obtain
comput
record
includ
basic
patient
demograph
prior
histori
haemoptysi
venou
thrombosi
complic
outcom
result
total
picc
insert
patient
male
femal
took
place
studi
period
twentyeight
percent
patient
histori
haemoptysi
one
fifth
prior
histori
dvt
pulmonari
embolu
major
patient
picc
line
insert
radiologist
rest
perform
nurs
practition
symptomat
dvt
pulmonari
embol
occur
conclus
audit
show
rate
piccassoci
dvt
adult
attend
wa
adult
cf
centr
equivoc
report
literatur
well
recognis
factor
includ
picc
size
thrombot
state
patient
cf
histori
dvt
impact
likelihood
piccassoci
dvt
follow
audit
plan
assess
role
enoxaparin
prophylaxi
particularli
outpati
set
aim
minimis
risk
picc
associ
dvt
introductionaim
pleural
fluid
ph
glucos
level
recommend
current
guidelin
investig
workup
pleural
effus
paramet
reduc
inflammatori
andor
metabol
activ
condit
whether
pleural
fluid
ph
glucos
level
provid
duplic
inform
independ
knowledg
unclear
aim
investig
relationship
pleural
fluid
ph
glucos
level
unselect
pleural
effus
incid
discord
level
method
set
pleural
servic
three
centr
spain
uk
australia
data
clinic
inform
pleural
fluid
ph
glucos
level
collect
analys
assess
relationship
ph
glucos
use
smooth
curv
restrict
cubic
spline
model
ii
concord
ph
glucos
vari
cutoff
level
assess
result
pleural
fluid
sampl
separ
four
categori
malign
bacteri
infect
tb
pleuriti
benign
effus
mean
ph
sd
median
glucos
rang
mmoll
linear
regress
model
relationship
glucos
logtransform
ph
restrict
cubic
spline
show
linear
p
nonlinear
effect
p
sampl
concord
ph
glucos
level
ie
cutoff
respect
concord
lowest
tb
group
highest
benign
pleuriti
group
patient
low
ph
high
glucos
like
diabet
diabet
vs
low
glucos
high
ph
p
bacteri
infect
introductionaim
indwel
pleural
cathet
ipc
effect
treatment
recurr
especi
malign
pleural
effus
pleural
infect
though
uncommon
remain
physician
major
concern
use
ipc
intrapleur
tpadnas
therapi
revolution
care
pleural
infect
use
ipcrel
pleural
infect
subject
prior
report
method
singl
centr
retrospect
review
patient
ipcrel
pleural
infect
treat
tpadnas
tertiari
pleural
unit
demograph
intervent
outcom
treatment
describ
introductionaim
bronchoscop
lung
volum
reduct
blvr
via
endobronchi
valv
ebv
insert
accept
treatment
patient
sever
emphysema
common
complic
ebv
insert
pneumothorax
report
incid
aim
studi
determin
previou
pleural
injuri
paraseptalpanlobular
emphysema
morpholog
subtyp
would
contribut
pneumothorax
risk
postebv
insert
australia
period
septemb
examin
centr
royal
adelaid
hospit
queen
elizabeth
hospit
chestcar
clinic
emphysema
subtyp
determin
evalu
preebv
ct
chest
scan
presenc
pleural
injuri
determin
assess
patient
previou
pneumothorax
pleural
instrument
pleural
plaquesnodul
preebv
ct
chest
scan
result
procedur
complet
within
studi
timefram
procedur
result
pneumothorax
mean
age
ebv
insert
year
ebv
insert
occur
male
patient
statist
analysi
undertaken
via
logist
regress
previou
pleural
injuri
significantli
increas
risk
pneumothorax
postebvi
confid
interv
p
gender
age
ebv
insert
paraseptalpanlobular
emphysema
subtyp
significantli
increas
pneumothorax
risk
conclus
first
australian
studi
examin
risk
factor
pneumothorax
incid
ebv
insert
previou
pleural
injuri
significantli
increas
pneumothorax
risk
ebv
insert
data
contribut
abil
predict
pneumothorax
patient
evalu
ebv
insert
thu
allow
improv
risk
assess
facilit
discharg
plan
postebv
insert
plan
studi
evalu
possibl
risk
factor
includ
quantit
ct
score
pleural
adhes
grant
support
none
introductionaim
obstruct
sleep
apnoea
osa
common
associ
signific
morbid
mortal
object
preval
data
australia
particularli
women
busselton
western
australia
preval
osa
respiratori
disturb
index
estim
men
men
women
apneahypopnea
index
ahi
particip
without
known
osa
assess
osa
preval
busselton
healthi
age
studi
comprehens
health
studi
sex
age
year
shire
elector
roll
born
invit
particip
particip
dual
channel
apnealink
devic
home
sleep
studi
issu
particip
collect
suitabl
analysi
preval
osa
defin
ahi
obtain
apnealink
autom
event
score
algorithm
relat
demograph
data
comorbid
assess
moder
sever
osa
defin
ahi
respect
result
preval
osa
ahi
men
women
see
tabl
increas
osa
sever
associ
increas
bmi
alcohol
use
sex
sleepi
men
preval
osa
busselton
increas
preval
women
higher
previous
report
sexbas
differ
comorbid
observ
breath
determin
via
presenc
bereitschaft
readi
potentiala
low
amplitud
neg
inspir
chronic
obstruct
pulmonari
diseas
copd
chang
lung
chest
wall
respiratori
muscl
induc
inspiratori
load
hypothesis
cortic
contribut
quiet
breath
copd
cortic
contribut
inspiratori
threshold
load
relat
dyspnoeaa
major
symptom
copd
method
electroencephalograph
activ
eeg
record
copd
patient
male
age
healthi
control
agematch
young
quiet
breath
inspiratori
threshold
load
maxim
inspiratori
pressur
two
blind
observ
evalu
presenc
bereitschaftspotenti
prior
inspir
ensembl
averag
epoch
eeg
cz
fcz
dyspnoea
rate
use
modifi
borg
scale
result
incid
cortic
contribut
quiet
breath
significantli
greater
copd
patient
young
p
agematch
p
control
cortic
contribut
inspiratori
threshold
load
associ
higher
borg
score
young
p
agematch
control
p
copd
patient
p
conclus
studi
provid
evid
age
rather
copd
associ
cortic
contribut
quiet
breath
cortic
contribut
inspiratori
threshold
load
may
associ
sever
dyspnoea
least
healthi
young
peopl
posit
airway
pressur
cpap
treatment
obstruct
sleep
apnea
osa
well
valid
benefit
qualiti
life
health
outcom
long
term
adher
remain
major
challeng
remot
access
cloud
base
technolog
becom
standard
featur
new
cpap
devic
current
featur
may
optim
utilis
improv
complianc
patient
experi
cpap
sought
determin
whether
remot
base
assess
cpap
usag
regular
interv
follow
telephon
assess
could
improv
cpap
usag
epworth
sleepi
score
ess
patient
commenc
cpap
therapi
osa
wellsupport
sleep
servic
method
sought
prospect
assess
consecut
patient
commenc
cpap
therapi
osa
patient
cpap
usag
remot
assess
week
post
commenc
telephon
assess
standardis
questionnair
carri
interv
cpap
usag
per
night
cpap
usag
final
ess
compar
consecut
retrospect
control
current
preliminari
data
includ
target
patient
intervent
group
introductionaim
mechan
ventil
lifesav
therapi
patient
respiratori
failur
contribut
mortal
induc
inflamm
lead
multisystem
organ
failur
differ
region
lung
shown
heterogen
respond
mechan
ventil
howev
associ
variat
region
lung
distens
region
lung
inflamm
unknown
aim
studi
assess
associ
healthi
lung
ventil
two
group
adult
balbc
mice
n
per
group
h
use
protect
low
tidal
volum
moder
posit
end
expiratori
pressur
peep
injuri
high
tidal
volum
zero
peep
ventil
strategi
rna
level
gene
quantifi
region
qpcr
array
gene
express
correl
region
frc
tidal
volum
distens
frc
tidal
volum
frc
tidal
volum
obtain
analysi
crosscorrelationbas
velocimetri
dynam
highresolut
phase
contrast
lung
imag
baselin
two
hour
ventil
result
two
gene
differenti
region
express
vari
ventil
strategi
p
express
gene
posit
correl
region
tidal
volum
distens
p
correl
express
cfo
also
vari
ventil
strategi
p
appear
associ
frc
tidal
volum
distens
demonstr
associ
region
gene
express
tidal
volum
result
provid
critic
insight
region
lung
respons
mechan
ventil
particular
result
highlight
import
balanc
underventil
overstretch
tidal
volum
contribut
lung
inflamm
potenti
patient
outcom
introductionaim
although
signific
progress
made
asthma
manag
patient
sever
asthma
sa
associ
increas
morbid
mortal
econom
burden
within
group
patient
prescrib
continu
nearcontinu
oral
corticosteroid
oc
achiev
maintain
asthma
control
howev
primari
care
subset
patient
may
exist
poor
asthma
manag
practic
thu
less
sever
diseas
reli
oc
achiev
asthma
control
instead
regular
inhal
prevent
medic
aim
studi
identifi
pattern
medic
take
behaviour
describ
respiratori
statu
peopl
asthma
primari
care
allow
develop
framework
identifi
patient
base
asthma
sever
medic
record
method
patient
data
utilis
qualitycontrol
commun
pharmaci
databas
correl
analysi
regress
model
employ
determin
potenti
predictor
asthmat
oral
corticosteroid
user
base
asthma
sever
lung
function
symptom
control
comorbid
adher
inhal
techniqu
medic
manag
result
fifteen
percent
asthmat
recruit
prescrib
oc
last
month
ninetythre
percent
oc
user
classifi
poor
asthma
control
identifi
potenti
barrier
nonadher
determin
brief
medic
questionnair
svarstad
bl
et
al
incorrect
inhal
techniqu
signific
relationship
found
oc
user
ownership
asthma
action
plan
p
exist
depress
eczema
potenti
nonadher
poor
asthma
control
p
poor
lung
function
test
higher
prescrib
rate
inhal
combin
therapi
p
includ
higher
rate
visit
doctor
regard
asthma
conclus
research
uncov
heterogen
group
peopl
asthma
primari
care
less
sever
diseas
put
risk
exacerb
due
medic
take
behaviour
better
understand
behaviour
individu
context
daytoday
manag
abl
tailor
intervent
patient
reflect
current
guidelin
like
report
presente
ci
time
like
report
daili
activ
impair
ci
poorer
asthma
control
exacerb
previou
year
associ
greater
absente
presente
activ
impair
p
worsen
asthma
control
score
associ
increas
presente
time
time
interact
particip
sever
asthma
wors
asthma
control
p
asthmarel
qualiti
life
p
depress
symptom
anxieti
symptom
associ
greater
odd
presente
conclus
impair
work
nonwork
function
import
compon
diseas
burden
sever
asthma
optimis
workplac
product
requir
improv
asthma
control
attent
mental
health
absente
presente
may
key
metric
assess
intervent
efficaci
among
peopl
sever
asthma
work
age
grant
support
sawd
support
gsk
roch
az
novarti
boehring
ingelheim
introductionaim
glucocorticoid
gc
remain
central
treatment
asthma
therapeut
respons
impair
sever
asthma
asthma
exacerb
laboratori
found
per
se
impair
gc
activ
key
mediat
viral
infectioninduc
gc
insensit
airway
epithelium
key
clock
compon
implic
signal
also
regul
gc
activ
current
studi
demonstr
target
prevent
gc
insensit
attenu
viru
mimic
poli
c
induc
inflammatori
respons
method
differenti
express
assess
ihc
human
asthmat
cohort
gc
respons
bronchial
epitheli
cell
airliquid
interfac
ali
differenti
primari
human
bronchial
epitheli
cell
hbec
presenc
assess
rtqpcr
greseap
poli
c
inflammatori
respons
cell
assess
elisa
potenti
involv
experiment
set
determin
use
pharmacolog
genet
sirna
approach
result
express
significantli
higher
airway
wall
sever
asthmat
compar
wellcontrol
asthma
healthi
subject
cell
alihbec
suppress
gcinduc
gre
activ
endogen
gene
express
prevent
poli
c
proinflammatori
introductionaim
improv
diagnost
tool
predict
airway
inflammatori
phenotyp
futur
exacerb
frequenc
asthma
requir
previous
demonstr
sputum
gene
express
signatur
biomark
could
predict
inflammatori
phenotyp
corticosteroid
respons
stabl
asthma
recent
demonstr
azithromycin
addon
treatment
uncontrol
moderatetosever
asthma
significantli
reduc
asthma
exacerb
amaz
clinic
trial
aim
test
whether
predict
airway
inflammatori
futur
exacerb
phenotyp
subpopul
amaz
clinic
trial
also
test
whether
week
azithromycin
treatment
alter
express
compar
placebo
method
patient
placebotr
azithromycintr
produc
adequ
sputum
differenti
cell
count
pcr
marker
baselin
week
treatment
logist
regress
roc
analysi
perform
baselin
result
compar
predict
valu
convent
biomark
airway
inflammatori
phenotyp
futur
exacerb
frequenc
result
significantli
predict
airway
inflammatori
subtyp
baselin
outperform
system
biomark
peripher
blood
eosinophil
pbe
fraction
exhal
nitric
oxid
feno
significantli
predict
futur
exacerb
phenotyp
numer
superior
biomark
examin
sputum
eosinophil
sputum
neutrophil
pbe
feno
identifi
patient
would
go
experi
frequent
sever
exacerb
azithromycin
treatment
significantli
alter
express
compar
placebo
affect
predict
exacerb
phenotyp
use
sputum
use
diagnost
tool
inflammatori
phenotyp
predict
futur
frequent
sever
exacerb
retain
predict
capac
azithromycintr
asthma
suggest
novel
therapeut
mechan
independ
known
exacerbationassoci
inflammatori
factor
method
recruit
adult
poorli
control
allerg
asthma
atop
one
aeroallergen
maxim
dose
inhal
corticosteroid
long
act
bronchodil
persist
poor
asthma
symptom
control
exacerb
requir
oral
corticosteroid
serum
total
ige
compar
healthi
age
match
control
asthma
atopi
particip
assess
prior
commenc
treatment
omalizumab
month
later
time
effect
treatment
assess
blood
drawn
peripher
blood
monocyt
pbmc
isol
pbmc
expos
hour
iav
rv
respons
assess
elisabead
arraywith
releas
interferon
ifn
result
baselin
visit
subject
sever
allerg
asthma
compar
healthi
control
demonstr
impair
releas
respons
iav
p
rv
follow
month
treatment
demonstr
improv
asthma
symptom
control
continu
treatment
clinic
respond
signific
increas
seen
iav
trend
toward
improv
rv
conclus
adult
sever
allerg
asthma
demonstr
impair
system
innat
immun
respons
iav
rv
treatment
omalizumab
result
improv
asthma
control
associ
improv
innat
antivir
respons
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
introductionaim
treatabl
trait
tt
propos
new
approach
airway
diseas
manag
howev
support
data
current
limit
aim
determin
identif
tt
possibl
use
sever
asthma
registri
assess
preval
sever
compar
nonsever
asthma
assess
relationship
tt
futur
exacerb
risk
method
sever
asthma
webbas
databas
observ
registri
sever
asthma
patient
comparison
group
patient
nonsever
asthma
site
australasia
year
femal
particip
characteris
enrol
follow
month
publish
trait
map
registri
data
field
preval
determin
bayesian
model
averag
appli
identifi
trait
best
predict
futur
exacerb
risk
result
seven
pulmonari
extrapulmonari
behaviour
riskfactor
trait
identifi
pulmonari
extrapulmonari
trait
express
sever
nonsever
asthma
p
trait
significantli
common
sever
asthma
incomplet
revers
airflow
limit
vs
frequent
exacerb
conclus
registrybas
systemat
characteris
asthma
may
use
assess
tt
report
trait
predict
exacerb
risk
confirm
greater
burden
associ
sever
asthma
trial
evalu
efficaci
costeffect
tt
approach
need
introductionaim
asthma
chronic
inflammatori
airway
diseas
character
recurr
attack
breathless
wheez
pathogenesi
asthma
complex
still
unclear
unfold
protein
respons
upr
endoplasm
reticulum
er
recent
identifi
play
decis
role
inflammatori
diseas
worsen
asthmat
condit
brought
stimuli
oxid
stress
pathogen
infect
allergen
exposur
induc
er
stress
activ
upr
activ
arm
upr
induc
differ
inflammatori
pathway
dysregul
innat
immun
respons
howev
upr
associ
asthma
unclear
investig
upr
signatur
differ
inflammatori
phenotyp
asthma
use
human
clinic
sampl
method
broncho
alveolar
lavag
fluid
balf
endobronchi
biopsi
induc
sputum
sampl
collect
eosinophil
neutrophil
paucigranulocyt
asthma
patient
healthi
individu
express
upr
associ
gene
balf
cell
biopsi
sampl
analys
qpcr
upr
relat
protein
express
analys
immunoblot
upr
gene
express
sputum
cell
analys
microarray
result
upr
gene
chop
lung
immun
cell
significantli
induc
p
eosinophil
asthma
neutrophil
asthma
demonstr
increas
trend
chop
protein
express
significantli
higher
eosinophil
neutrophil
group
microarray
data
sputum
cell
demonstr
upregul
variou
upr
gene
mostli
eosinophil
asthma
group
paucigranulocyt
mix
granulocyt
group
upr
gene
express
lung
biopsi
show
signific
differ
group
howev
bronchial
epitheli
cell
bec
treat
asthma
allergen
demonstr
increas
trend
upr
conclus
upr
heighten
eosinophil
neutrophil
asthma
airway
immun
cell
major
role
regul
upr
airway
asthma
respirolog
hypothesi
hypothesis
profibrot
effect
involv
b
cellmedi
immun
regul
effect
therapi
bleomycintr
wildtyp
mice
lung
fibrosi
immun
cell
composit
examin
mice
given
two
dose
antibodi
genentech
inc
usa
isotyp
control
ip
either
day
prior
day
bleomycin
day
day
postbleomycin
treatment
follow
initi
fibrosi
extent
fibrosi
measur
day
result
fac
analysi
blood
taken
day
day
postbleomycintreat
reveal
almost
complet
deplet
b
cell
circul
wildtyp
mice
howev
extent
fibrosi
assess
use
microct
imag
hplc
analysi
hydroxyprolin
level
significantli
differ
treatment
group
histolog
analysi
reveal
abund
b
cell
plasma
cell
lung
mice
fac
analysi
identifi
expans
day
cell
lung
bleomycin
treat
mice
day
conclus
although
antibodi
deplet
follicular
b
cell
effect
bleomycininduc
fibrosi
residu
plasma
cell
b
abund
lung
bleomycintr
mice
activ
b
cell
subset
may
contribut
fibrot
phenotyp
introduct
class
iii
naddepend
histon
deacetylas
hdac
sirtuin
import
regul
senesc
age
inflamm
deacetyl
chromatin
histon
therebi
silenc
inflammatori
gene
transcript
report
increas
steroid
resist
senesc
proinflammatori
cell
patient
copd
hypothes
express
would
reduc
cell
copd
treatment
activ
resveratrol
agent
prevent
nad
deplet
theophyllin
would
upregul
express
reduc
proinflammatori
cytokin
express
steroid
resist
cell
method
blood
collect
copd
patient
age
match
control
express
proinflammatori
cytokin
determin
nktlike
cell
cultur
presenc
ae
resveratrol
ae
theophyllin
ae
prednisolon
use
flow
cytometri
nktlike
cell
compar
counterpart
patient
control
eg
vs
loss
associ
increas
product
steroid
resist
express
upregul
presenc
resveratrol
theophyllin
associ
decreas
steroid
resist
product
nktlike
cell
conclus
steroid
resist
proinflammatori
nktlike
cell
associ
decreas
express
combin
resveratrol
andor
theophyllin
treatment
increas
express
restor
steroid
sensit
inhibit
proinflammatori
cytokin
product
cell
may
reduc
system
inflamm
copd
grant
support
introductionaim
women
higher
incid
asthma
compar
men
exacerb
women
often
sever
correl
high
estrogen
level
use
experiment
anim
model
asthma
observ
femal
rat
experiment
asthma
also
develop
sever
exacerb
compar
male
rat
aim
studi
investig
femal
sex
hormon
estrogen
impact
asthma
respons
identifi
immunolog
mechan
effect
method
implant
estrogenreleas
pellet
male
rat
prior
ovalbuminsensitis
rechalleng
investig
estrogenexpos
male
respond
compar
untreat
male
femal
use
multi
paramet
flow
cytometri
investig
proport
activ
antigen
present
dendrit
cell
respond
effector
regulatori
cell
airway
allergen
rechalleng
result
discov
estrogen
suffici
induc
femalelik
diseas
phenotyp
exacerb
male
rat
interestingli
male
femal
rat
also
display
signific
differ
cell
ratio
airway
drain
lymph
node
directli
impact
estrogen
exposur
addit
femal
estrogen
treat
male
rat
male
rat
display
sign
recruit
cell
airway
follow
allergen
rechalleng
like
contribut
exacerb
respons
conclus
data
suggest
estrogen
suffici
induc
femal
like
asthma
symptom
male
rat
appear
alter
cell
balanc
promot
allerg
respons
grant
support
studi
fund
asthma
foundat
western
australia
telethon
kid
institut
swedish
societi
medic
research
introduct
aim
small
molecul
correct
cftr
product
function
greatli
improv
cf
outcom
rarer
mutat
hinder
lack
appropri
primari
cultur
model
modifi
primari
airway
epitheli
cell
aec
children
cf
modifi
express
fluoresc
marker
allow
function
cftr
assess
would
provid
culturebas
highthroughput
screen
platform
compar
methodolog
achiev
stabl
fluoresc
primari
aec
method
primari
aec
obtain
children
cf
noncf
bronchial
brush
cultur
use
condit
reprogram
methodolog
cell
transfect
plasmid
via
lipofectamin
devic
altern
aec
transduc
replicationdefici
retrovir
vector
fluoresc
tag
hour
cell
express
fluoresc
select
fluoresc
activ
cell
sort
fac
flow
cytometri
expand
cultur
assess
stabil
gene
express
result
primari
aec
amen
three
methodolog
transfect
lipofectamin
effici
best
electropor
protocol
achiev
slightli
higher
effici
replic
defici
retroviru
effect
posit
cell
differ
transfect
effici
observ
noncf
cf
aec
cell
could
success
cultur
fac
select
aec
transduc
retrovir
vector
maintain
fluoresc
two
passag
cultur
second
lead
caus
avoid
hospit
admiss
australia
date
nation
data
exist
compar
recommend
clinic
practic
guidelin
inpati
manag
acut
exacerb
actual
practic
aim
compar
contemporari
manag
recommend
copdx
guidelin
method
prospect
audit
copd
hospit
admiss
five
tertiari
care
hospit
five
state
australia
conduct
standardis
audit
tool
use
collect
data
telephon
followup
day
discharg
assess
readmiss
healthstatu
data
assess
copdx
guidelin
result
prospect
data
obtain
admiss
patient
octob
meanaesd
age
year
male
caucasian
mean
number
comorbid
per
patient
hypertens
gastrointestin
diseas
ischaem
heart
diseas
psychiatricanxietydepress
disord
preval
half
exsmok
live
home
anoth
patient
readmit
within
day
inpati
death
death
within
day
discharg
concord
copdx
recommend
vari
prescript
oral
corticosteroid
introduct
flame
studi
demonstr
superior
indacaterolglycopyrronium
daili
reduc
exacerb
improv
lung
function
health
statu
versu
salmeterolfluticason
moderatetoveri
sever
copd
patient
histori
exacerb
assess
effect
indacaterolglycopyrronium
versu
salmeterolfluticason
rate
risk
moder
sever
exacerb
subset
gold
group
patient
histori
exacerb
hospit
exacerb
flame
studi
method
flame
random
doubleblind
doubledummi
parallelgroup
studi
patient
moderatetoveri
sever
copd
postbronchodil
fev
predict
normal
histori
exacerb
previou
year
random
receiv
either
indacaterolglycopyrronium
oncedaili
salmeterolfluticason
twicedaili
rate
time
moder
sever
exacerb
analyz
subset
gold
group
patient
result
patient
random
categor
gold
group
mean
postbronchodil
fev
predict
normal
valu
patient
ic
screen
indacaterolglycopyrronium
demonstr
superior
efficaci
salmeterolfluticason
reduc
rate
moder
sever
exacerb
rate
ratio
tabl
indacaterolglycopyrronium
delay
timetofirst
moder
sever
exacerb
compar
salmeterolfluticason
median
day
versu
tabl
patient
treat
indacaterolglycopyrronium
lower
risk
moder
sever
exacerb
compar
salmeterolfluticason
conclus
indacaterolglycopyrronium
superior
salmeterol
fluticason
reduc
rate
risk
moder
sever
exacerb
subset
gold
group
patient
histori
exacerb
hospit
exacerb
confirm
use
prefer
treatment
option
copd
patient
high
risk
exacerb
grant
support
novarti
pharma
ag
basel
univers
south
australia
adelaid
south
australia
australia
introduct
famili
aggreg
chronic
lung
condit
may
result
combin
genet
suscept
exposur
risk
factor
throughout
life
use
lifecours
approach
investig
factor
contribut
relationship
parent
respiratori
diseas
histori
reduc
lung
health
rlh
adulthood
use
data
british
birth
cohort
studi
method
cohort
particip
characteris
term
rlh
presenc
respiratori
symptom
airway
obstruct
parent
histori
respiratori
diseas
offspr
age
lifecours
factor
evalu
matern
smoke
live
smoker
social
class
respiratori
ill
smoke
statu
occup
exposur
dust
fume
operationalis
life
period
birth
childhood
adulthood
path
analysi
use
investig
mediat
role
lifecours
factor
relationship
parent
respiratori
diseas
histori
rlh
adjust
gender
asthma
recent
chest
infect
result
within
cohort
parent
respiratori
histori
offspr
rlh
parent
respiratori
histori
posit
associ
rlh
matern
smoke
pregnanc
person
smoke
adulthood
social
class
occup
exposur
dust
fume
factor
relat
parent
histori
rlh
mediat
pathway
test
indic
sequenc
matern
adulthood
smoke
contribut
model
fit
indirect
effect
explain
parent
historyrlh
relationship
conclus
associ
parent
histori
respiratori
diseas
offspr
rlh
partli
mediat
sequenc
exposur
matern
smoke
smoker
adulthood
larg
proport
relationship
parent
historyrlh
remain
unexplain
smoke
suggest
assess
parent
histori
respiratori
diseas
may
provid
insight
earlier
diagnosi
intervent
grant
support
australian
govern
research
train
program
scholarship
lsk
li
enc
pathophysiolog
phenomena
also
depend
lung
volum
presenc
airway
closur
oscil
pressur
wave
abl
penetr
lung
segment
may
relat
total
thorac
ga
volum
singlebreath
alveolar
volum
va
measur
diffus
capac
test
estim
commun
ga
volum
dilut
breath
hold
ratio
va
plethysmograph
total
lung
capac
tlc
vatlc
therefor
reduc
obstruct
airway
diseas
due
incomplet
ga
mix
ga
trap
hypothesis
would
relat
vatlc
tlc
copd
method
subject
mildmoder
copd
male
mean
rang
age
mean
ae
sd
pred
ae
test
use
fot
thorasi
tremoflo
normal
tidal
breath
spirometri
bodi
plethysmographi
singlebreath
diffus
capac
test
perform
accord
standard
qualiti
criteria
spearman
rank
correl
coeffici
determin
adjust
known
covari
publish
refer
equat
result
moder
correl
vatlc
r
p
va
r
p
tlc
adjust
known
covari
zscore
remain
moder
correl
vatlc
r
p
va
tlc
zscore
vatlc
correl
sever
airflow
obstruct
measur
ratio
zscore
r
p
conclus
copd
measur
fot
normal
tidal
breath
reflect
commun
lung
volum
rather
total
lung
volum
fot
therefor
may
compliment
tradit
lung
function
measur
introductionaim
six
minut
walk
test
remain
commonli
use
clinic
measur
exercis
capac
pulmonari
hypertens
ph
whilst
maxim
exercis
test
use
cardiopulmonari
exercis
test
cpet
remain
gold
standard
estim
exercis
capac
test
much
less
common
clinic
practic
purpos
studi
compar
physiolog
respons
cpet
group
ph
subject
function
class
iiii
complet
cpet
cycl
ergomet
separ
day
test
ga
exchang
measur
use
calibr
portabl
metabol
system
cortex
metamax
oxygen
uptak
vo
carbon
dioxid
product
vco
ventil
v
e
heart
rate
hr
oxygen
puls
v
e
vco
end
tidal
carbon
dioxid
p
et
co
oxygen
satur
p
breathless
borg
averag
final
compar
cpet
subgroup
particip
end
exercis
lactat
hla
also
measur
use
portabl
lactat
analys
lactat
scout
mean
peak
power
achiev
particip
ae
w
whilst
mean
distanc
ae
signific
differ
cpet
peak
vo
cpet
vs
mlkg
min
v
e
vs
lmin
hr
vs
beatsmin
puls
vs
mlbeat
v
e
vs
p
et
co
vs
mmhg
vs
ae
peak
vco
vs
lmin
breathless
vs
lactat
vs
significantli
higher
p
cpet
found
physiolog
respons
cpet
group
ph
particip
similar
would
suggest
similar
peak
exercis
challeng
ph
popul
introductionaim
pulmonari
rehabilit
pr
cycl
train
recommend
peak
oxygen
uptak
measur
cardiopulmonari
exercis
test
cpet
howev
access
cpet
limit
estim
equival
intens
walk
distanc
use
publish
equat
associ
substanti
variat
studi
aim
investig
whether
submaxim
cycl
exercis
test
smct
prescrib
appropri
cycl
train
intens
whether
initi
train
intens
estim
smct
similar
method
retrospect
data
collect
patient
attend
pr
previou
month
patient
routin
perform
walk
test
baselin
complet
smct
second
exercis
session
subsequ
exercis
session
cycl
train
prescrib
peak
work
watt
achiev
smct
initi
intens
consid
appropri
patient
could
complet
minut
prescrib
report
dyspnoea
andor
rpe
score
borg
score
result
fortythre
patient
male
chronic
lung
diseas
copd
ild
includ
mean
sd
age
metr
smct
peak
work
watt
eight
one
percent
patient
achiev
target
intens
found
initi
workload
easi
unabl
maintain
target
intens
moder
correl
work
rate
predict
watt
smct
watt
r
p
estim
cycl
train
intens
overpredict
watt
appropri
train
patient
underpredict
chronic
lung
diseas
prescrib
cycl
exercis
intens
smct
peak
work
achiev
appropri
train
intens
toler
patient
prescrib
work
rate
smct
result
similar
train
load
although
smct
may
provid
accur
cycl
train
intens
introductionaim
increas
dietari
fat
associ
increas
risk
asthma
airway
hyperrespons
singl
high
fat
meal
reduc
efficaci
salbutamol
suggest
dietari
fatti
acid
may
alter
airway
smooth
muscl
asm
contractil
therefor
aim
determin
effect
fatti
acid
vitro
bovin
tracheali
smooth
muscl
respons
relax
contractil
stimuli
method
oleic
acid
linol
acid
alphalinolen
acid
palmit
acid
stearic
acid
elaid
acid
compar
bovin
tracheali
muscl
strip
n
mount
tissu
bath
warm
aerat
kreb
solut
experi
done
presenc
tetradotoxin
test
sensit
relax
stimuli
muscl
strip
contract
acetylcholin
half
maxim
effect
concentr
ec
addit
vehicl
fatti
acid
cumul
doserespons
curv
isoproterenol
perform
test
sensit
contractil
stimuli
separ
muscl
strip
incub
vehicl
fatti
acid
cumul
doserespons
curv
acetylcholin
perform
result
relax
experi
asm
forc
follow
acetylchoin
affect
addit
fatti
acid
similarli
effect
fatti
acid
ec
concentr
isoproterenol
ranova
p
contract
experi
baselin
forc
unalt
addit
fatti
acid
similarli
effect
fatti
acid
ec
acetylcholin
ranova
p
sensit
ultraperform
liquidchromatographi
tandem
massspectrometri
assay
quantif
piptaz
method
drug
extract
human
plasma
pleural
fluid
protein
precipit
methanol
contain
intern
standard
piperacillind
sulbactam
sampl
mix
methanol
contain
vortex
centrifug
supernat
dilut
mobil
phase
contain
ammonium
bicarbon
water
chromatograph
separ
achiev
use
acquiti
beh
column
method
appli
two
patient
pleural
infect
six
pleural
fluid
blood
sampl
obtain
steadyst
postinfus
select
specif
precis
accuraci
matrix
effect
stabil
result
within
accept
limit
patient
time
maximum
concentr
c
max
pip
taz
pleural
fluid
delay
compar
plasma
c
max
pip
pleural
fluid
reach
patient
c
max
achiev
plasma
patient
respect
introductionaim
bronchiectasi
relat
cystic
fibrosi
noncf
bex
increasingli
recognis
caus
chronic
lung
diseas
occur
isol
lung
diseas
includ
asthma
copd
set
bronchiectasi
associ
signific
health
care
utilis
impact
australia
new
zealand
poorli
understood
includ
indigen
popul
aim
describ
impact
noncf
bex
inpatinet
hospit
care
set
method
multicentr
australian
new
zealand
retrospect
audit
hospit
admiss
data
relat
patient
noncf
bex
admit
five
hospit
melbourn
sydney
alic
spring
australia
auckland
new
zealand
undertaken
number
length
stay
lo
respiratori
admiss
determin
melbourn
alic
spring
auckland
addit
inform
obtain
regard
requir
ventilatori
support
result
data
regard
hospitalis
present
conclus
health
care
utilis
noncf
bex
substanti
number
admiss
vari
substanti
site
cummul
lo
averag
lo
also
vari
australian
patient
longer
lo
compar
nz
patient
indigen
australian
patient
shorter
lo
compar
nonindigen
counterpart
despit
frequent
admiss
overal
greater
hospitalis
day
lo
compar
copd
rang
day
australia
frequenc
admiss
noncf
bex
like
major
factor
drive
hospitalbas
health
care
utilis
utilis
ventilatori
support
vari
countri
particularli
high
indigen
australian
impact
optim
level
admiss
frequenc
lo
ventilatori
support
susequ
represent
hospit
qualiti
life
surviv
focu
investig
introductionaim
sever
influenza
infect
children
chronic
lung
diseas
result
unschedul
hospit
present
substanti
burden
health
system
nation
influenza
burden
data
children
chronic
lung
diseas
limit
data
crucial
monitor
burden
diseas
evalu
effect
influenza
vaccin
program
conduct
retrospect
populationbas
cohort
studi
measur
impact
influenza
hospitalis
rate
children
chronic
lung
diseas
perform
retrospect
cohort
studi
use
populationbas
link
administr
data
children
born
new
south
wale
complet
followup
decemb
cohort
divid
two
group
children
chronic
lung
diseas
includ
children
asthma
bronchopulmonari
dysplasia
cystic
fibrosi
congenit
lung
disord
ii
standardrisk
children
primari
outcom
episod
influenza
associ
hospitalis
icd
code
incid
rate
influenza
hospitalis
calcul
use
poisson
estim
calcul
confid
interv
around
incid
result
cohort
compris
children
chronic
lung
diseas
standardrisk
children
adjust
childyear
influenza
hospitalis
children
chronic
lung
diseas
standardrisk
children
ci
rate
children
chronic
lung
diseas
rang
childyear
childyear
similar
male
femal
children
chronic
lung
diseas
ci
boy
ci
girl
studi
demonstr
children
chronic
diseas
least
five
time
risk
hospitalis
influenza
standardrisk
children
futur
studi
investig
effect
univers
vaccin
program
children
may
help
reduc
burden
compromis
asthma
control
increas
burden
diseas
especi
among
poorlycontrol
symptom
studi
assess
percept
control
depend
reliev
medic
among
patient
take
saba
alon
method
crosssect
populationbas
internet
survey
particip
current
asthma
age
year
use
likerttyp
question
rang
strongli
disagre
strongli
agre
survey
captur
attitud
asthma
asthma
treatment
asthma
control
assess
use
asthma
control
test
act
poorlycontrol
wellcontrol
result
sabaonli
respond
poor
symptom
control
compar
sabaonli
user
wellcontrol
symptom
almost
time
like
agreestrongli
agre
felt
anxiou
without
reliev
vs
respect
p
almost
twice
like
feel
anxiou
without
reliev
around
trigger
vs
respect
p
addit
poorlycontrol
vs
wellcontrol
symptom
like
agreestrongli
agre
reli
reliev
asthma
vs
respect
p
reliev
lifesav
vs
respect
p
half
respond
group
agreedstrongli
agre
reliev
gave
control
asthma
vs
respect
conclus
patient
poor
symptom
control
appear
overli
reliant
saba
compar
patient
wellcontrol
asthma
optim
asthma
control
popul
requir
prevent
treatment
half
sabaonli
respond
view
reliev
mean
achiev
control
asthma
given
public
messag
control
asthma
aim
encourag
prevent
use
may
inadvert
give
opposit
messag
mani
peopl
data
call
question
preventerrelievercontrol
paradigm
current
use
terminolog
interact
better
patient
thought
belief
may
effect
weight
offspr
record
week
age
point
euthan
tracheasectomi
perform
trachea
segment
studi
organ
bath
chamber
measur
isometr
forc
product
carbachol
subsequ
fix
morphometri
maxim
activ
tension
stress
calcul
forc
normalis
segment
length
asm
crosssect
area
respect
result
iugr
offspr
lighter
birth
control
iugr
p
remain
lighter
week
age
compar
control
control
iugr
p
activ
tension
p
stress
p
reduc
male
iugr
offspr
compar
control
differ
asm
thick
statist
differ
activ
tension
stress
iugr
femal
offspr
despit
reduct
asm
thick
p
sensit
asm
contractil
agonist
alter
iugr
conclus
persist
effect
iugr
matur
airway
wall
favour
reduc
contract
asm
layer
includ
lower
asm
contractil
male
offspr
thinner
asm
layer
femal
offspr
find
suggest
alter
develop
fetal
airway
impact
suscept
futur
airway
diseas
chang
asm
structur
function
contract
airway
smooth
muscl
asm
layer
absenc
exogen
stimulu
term
intrins
tone
may
contribut
airflow
limit
aim
studi
assess
underli
structur
determin
asm
intrins
tone
peripher
human
airway
method
subject
year
undergo
lung
resect
surgeri
recruit
baselin
lung
function
assess
prior
surgeri
peripher
airway
dissect
resect
tissu
cut
bronchial
ring
ringssubject
measur
forc
organ
bath
chamber
lengthtens
curv
construct
kcl
mm
establish
optimum
length
l
contract
subsequ
adapt
repeat
kcl
stimul
experi
perform
l
tension
mnmm
ring
determin
complet
relax
theophyllin
fix
stereolog
section
stain
use
masson
trichom
techniqu
rel
fraction
asm
vv
asm
ecm
vv
ecm
within
asm
layer
measur
point
count
muscl
tension
convert
stress
mnmm
normalis
muscl
thick
result
subject
prebronchodil
fev
pred
fev
fvc
bronchial
ring
exhibit
mean
intrins
stress
intrins
stress
neg
correl
vv
ecm
p
posit
correl
vv
asm
p
also
nonsignific
trend
decreas
fev
pred
increas
intrins
stress
associ
lung
function
vv
ecm
vv
asm
presenc
intrins
stress
peripher
asm
layer
determin
underli
layer
composit
increas
greater
muscl
fraction
decreas
ecm
fraction
respect
propos
muscl
composit
affect
lung
function
regul
intrins
tone
shivappa
n
hebert
j
hodg
lung
function
turn
develop
andor
progress
chronic
inflammatori
lung
diseas
studi
assess
relationship
dietari
inflammatori
index
dii
literaturederiv
measur
inflammatori
potenti
diet
lung
function
aim
investig
relationship
populationbas
sampl
middleag
adult
method
random
sampl
middleag
adult
year
inner
southeast
melbourn
assess
spirometri
questionnair
energyadjust
dii
calcul
particip
semiquantit
food
frequenc
questionnair
regress
method
use
model
relationship
dii
quintil
lung
function
outcom
adjust
age
gender
height
energi
intak
bmi
asthma
atopi
smoke
asthma
statu
also
examin
effect
modifi
result
associ
dii
fev
dii
fvc
differ
asthma
statu
respect
current
asthmat
diet
highest
dii
quintil
mean
fev
lower
lowest
dii
quintil
ci
p
trend
mean
fvc
lower
ci
p
trend
remit
asthmat
diet
highest
dii
quintil
mean
fev
lower
lowest
dii
quintil
ci
p
trend
mean
fvc
lower
ci
p
trend
never
asthma
associ
dii
lung
function
measur
also
associ
dii
fev
fvc
asthma
categori
conclus
proinflammatori
diet
associ
poorer
lung
function
current
remit
asthmat
associ
causal
argu
low
inflammatori
diet
peopl
histori
asthma
introductionaim
vocal
cord
dysfunct
vcd
often
mistaken
sever
asthma
accur
diagnosi
crucialbut
difficult
treatment
complex
dedic
followup
essenti
examin
optim
overal
manag
vcd
multidisciplinari
team
mdt
clinic
initi
operation
type
clinic
yet
describ
method
patient
suspect
vcd
refer
respiratori
physician
ent
surgeon
clinic
staf
respiratori
physician
ent
surgeon
laryngologist
speech
therapist
respiratori
nurs
specialist
patient
complet
questionnair
spirometri
dynam
ct
larynx
prior
review
review
team
histori
obtain
physic
examin
conduct
laryngoscopi
perform
diagnosi
vcd
base
detect
ct
larynx
laryngoscopi
inspiratori
paradox
vocal
cord
movement
pvcm
least
one
occas
team
final
review
data
like
diagnosi
formul
treatment
select
consult
patient
result
total
patient
report
establish
asthma
diagnosi
vcd
establish
case
elect
access
speech
therapi
servic
base
symptom
speech
therapi
gaug
unsuccess
patient
individu
elect
botulinum
toxin
inject
second
group
case
diagnosi
vcd
consid
unlik
group
patient
poorli
control
asthma
patient
diagnos
third
group
patient
vcd
strongli
suspect
confirm
patient
offer
speech
therapi
success
achiev
case
conclus
vcd
mdt
clinic
establish
provid
integr
multidisciplinari
approach
diagnosi
manag
vcd
experi
indic
strategi
feasibl
employ
optimis
manag
problemat
condit
introductionaim
treatabl
trait
propos
new
paradigm
airway
diseas
manag
aim
determin
preval
trait
sever
asthma
copd
compar
healthi
control
compar
trait
preval
diagnost
label
method
particip
sever
asthma
copd
agematch
healthi
control
recruit
cross
section
studi
underw
clinicbas
multidimension
assess
characteris
treatabl
trait
result
recruit
sever
asthma
copd
healthi
control
particip
overal
meanaesd
age
year
femal
copd
particip
older
compar
sever
asthma
healthi
control
p
postbronchodil
fev
predict
lower
copd
compar
sever
asthma
healthi
control
p
possibl
trait
significantli
identifi
copd
sever
asthma
compar
healthi
control
p
signific
differ
copd
sever
asthma
p
howev
number
comorbid
differ
diseas
group
copd
versu
sever
asthma
trait
preval
copd
compar
sever
asthma
dyspnoea
p
exert
desatur
p
mucoushypersecret
p
airflow
limit
p
sever
asthma
significantli
daytimesleepi
p
musculoskelet
problem
p
obes
p
upperairway
diseas
p
dermat
p
airwayeosinophilia
common
sever
asthma
airwayneutrophilia
system
inflamm
copd
p
p
respect
preval
frequent
chest
infect
pathogen
colonis
smoke
nonadher
inhalerpolypharmaci
dysfunct
breath
reflux
anxieti
depress
differ
copd
sever
asthma
conclus
studi
confirm
heterogen
copd
sever
asthma
multidimension
assess
chronic
airway
diseas
allow
detect
trait
target
use
precis
medicin
approach
trial
test
approach
need
advanc
manag
introductionaim
increas
evid
highlight
cellular
senesc
contribut
idiopath
pulmonari
fibrosi
ipf
dna
damag
respons
ddr
senesc
also
lead
escal
mitochondri
superoxid
product
reinforc
senesc
studi
characteris
senesc
lung
fibroblast
ipf
patient
ipflf
agematch
control
ctrllf
delin
role
mitochondria
senesc
stabil
method
fibroblast
senesc
assess
use
composit
set
marker
includ
express
activ
measur
pcr
cytochem
stain
respect
ddr
detect
format
nuclear
foci
use
immunofluoresc
senescentassoci
secretori
phenotyp
sasp
characteris
measur
increas
cytokin
product
inflammatori
gene
express
elisa
nanostr
technolog
respect
mitochondri
dysfunct
monitor
increas
mitochondri
stress
mass
superoxid
use
fluorogen
dye
nnonylacridin
orang
mitotrack
green
mitosox
respect
result
even
earli
passag
ipflf
senescentlik
ctrllf
exhibit
intensifi
ddr
sasp
mitochondri
dysfunct
dna
damag
agent
etoposid
augment
senesc
ctrllf
accompani
heighten
mitochondri
stress
mass
superoxid
product
howev
effect
ipflf
mitochondri
perturb
rotenon
also
evok
ddr
senesc
ctrllf
inhibit
regul
mitochondri
function
incub
antioxid
nacetyl
cystein
attenu
pharmacologicalinduc
senesc
carri
identifi
basal
differ
express
ecm
epigenet
gene
target
copd
noncopd
smoker
qpcr
carri
confirm
microarray
analys
determin
effect
epigenet
inhibitor
resultsconclus
asm
cell
copd
patient
show
augment
tnc
express
respons
stimul
compar
cell
smoker
without
copd
inhibit
tsa
effect
tnc
express
cell
patient
group
whilst
inhibit
express
copd
treatment
significantli
abrog
express
copd
noncopd
group
whilst
express
abrog
copd
tnc
noncopd
express
significantli
repress
curcumin
treatment
noncopd
group
differ
respons
noncopd
suscept
smoker
copd
group
highlight
epigenet
differ
diseas
target
histon
acetyl
may
therapeut
option
small
airway
fibrosi
copd
signific
differ
seen
sleep
paramet
sol
tst
waso
se
pr
p
intervent
group
p
within
pr
group
associ
sleep
paramet
measur
qualiti
life
function
pr
attend
greater
proport
pr
session
moder
associ
tst
end
rehabilit
r
conclus
sleep
qualiti
measur
object
use
actigraphi
improv
pr
programm
individu
copd
whether
ongo
particip
regular
exercis
train
beyond
durat
pr
may
influenc
sleep
qualiti
yet
determin
tabl
conclus
use
exacerb
histori
alon
gold
rather
combin
lung
function
result
patient
classifi
gold
ab
lead
statist
power
investig
differ
monotherapi
use
strategi
greater
impact
sgrq
tdi
monotherapi
gold
ab
patient
show
reduc
loss
fev
subgroup
patient
current
guidelin
recommend
treatment
pi
fev
predict
howev
relationship
effect
treatment
lung
structur
preserv
fev
unclear
aim
assess
effect
treatment
relat
baselin
fev
predict
measur
chang
comput
tomographi
ct
lung
densiti
patient
random
rapid
baselin
fev
predict
method
chang
annual
ct
lung
densiti
declin
rate
activ
placebo
treat
patient
calcul
year
random
slope
intercept
model
baselin
fev
treatment
group
covari
use
analys
influenc
treatment
effect
result
baselin
lung
function
impair
affect
longterm
chang
lung
densiti
pn
regress
line
flat
activ
treatment
associ
lung
densiti
preserv
p
regress
line
parallel
placebo
treat
patient
regress
line
rate
annual
lung
densiti
declin
vs
baselin
flat
interact
treatment
group
baselin
fev
conclus
data
demonstr
patient
aatd
treat
pi
therapi
deriv
equal
benefit
term
lung
tissu
preserv
independ
pretreat
fev
grant
support
rapid
trial
programm
prepar
abstract
support
csl
behr
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
introductionaim
forcep
biopsi
guid
sheet
locat
lesion
use
radial
probe
ebu
establish
techniqu
diagnosi
solitari
pulmonari
modul
spn
yield
howev
drop
significantli
lesion
concentr
furthermor
forcep
often
provid
small
sampl
occasion
fall
short
provid
inform
requir
malign
use
cryoprob
combin
radial
ebu
could
potenti
provid
larger
sampl
increas
yield
nonconcentr
lesion
method
patient
underw
radial
ebu
cryobiopsi
diagnosi
spn
concord
macquari
univers
hospit
sydney
includ
studi
retrospect
audit
undertaken
obtain
demograph
baselin
physiolog
procedur
data
complic
length
stay
record
yield
determin
histopatholog
clinic
data
result
total
patient
femal
mean
age
year
far
includ
studi
procedur
perform
gener
anesthesia
rigid
intub
use
case
lesion
locat
case
use
ebu
radial
probe
one
eccenter
lesion
target
locat
upper
lobe
averag
biopsi
obtain
case
pneumothorax
sever
bleed
observ
two
patient
stay
overnight
procedur
averag
diamet
specimen
definit
malign
patholog
diagnos
case
overal
yield
conclus
radial
ebu
cryobiopsi
feasabl
altern
diagnosi
spn
yield
compar
previous
report
techniqu
howev
larger
specimen
obtain
cryobiopsi
could
potenti
provid
invalu
data
malign
condit
introductionaim
histolopatholog
often
requir
achiev
multidisciplinari
diagnosi
diffus
parenchym
lung
diseas
surgic
lung
biopsi
slb
remain
gold
standard
associ
signific
morbid
mortal
recent
emerg
transbronchi
cryobiopsi
tbcb
potenti
altern
slb
promis
less
complic
compar
yield
divid
world
intervent
pulmonolog
numer
public
report
differ
occasion
contradict
outcom
despit
rel
popular
tbcb
region
far
publish
seri
australia
univers
liverpool
hospit
sydney
diagnosi
diffus
parenchym
lung
diseas
august
june
includ
retrospect
audit
undertaken
obtain
demograph
baselin
physiolog
procedur
data
complic
length
stay
record
diagnost
valu
tbcb
assess
histopatholog
clinic
impact
biopsi
specimen
review
singl
investig
record
size
presenc
artefact
percentag
alveolar
area
presenc
pleura
proxim
airway
structur
result
total
patient
male
averag
age
enrol
studi
case
perform
gener
anaesthesia
rigid
bronchoscop
access
averag
biopsi
obtain
lobe
patient
discharg
home
day
averag
length
stay
night
pneumothorax
observ
patient
sever
endobronchi
bleed
death
report
within
day
procedur
histopatholog
data
well
yield
current
analys
conclus
preliminari
data
suggest
tbcb
rel
safe
procedur
accept
yield
could
consid
altern
slb
grant
support
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
introductionaim
emphysema
lead
caus
disabl
death
current
medic
treatment
show
certain
limit
advanc
stage
diseas
also
limit
evid
australian
set
regard
therapeut
intervent
reduc
hyperinfl
includ
endobronchi
valv
insert
ebv
studi
examin
outcom
ebv
insert
patient
sever
emphysema
royal
brisban
women
hospit
method
retrospect
review
patient
sever
emphysema
underw
ebv
insert
primari
outcom
chang
exercis
toler
measur
sixminut
walk
test
qualiti
life
qol
measur
st
georg
respiratori
questionnair
sgrq
direct
question
variabl
interest
measur
preand
postebv
placement
result
patient
includ
studi
femal
age
rang
year
median
year
sixteen
patient
complic
patient
multipl
complic
three
patient
readmit
within
day
die
mainli
due
oldag
comorbid
ninetyday
mortal
rate
pre
post
valu
obtain
patient
sgrq
patient
qol
data
patient
patient
complet
data
show
improv
mean
valu
sgrq
lung
function
mean
sgrq
reduc
unit
increas
metr
mean
increas
residu
volum
tlc
reduc
respect
signific
improv
qol
report
patient
report
improvementslight
improv
conclus
ebv
effect
safe
therapi
improv
lung
function
exercis
capac
qol
select
patient
emphysema
studi
larger
popul
need
confirm
find
introductionaim
random
control
trial
bronchial
thermoplasti
bt
proven
reduc
symptom
sever
asthma
mechan
achiev
still
uncertain
improv
spirometri
observ
studi
postul
bt
might
improv
lung
mechan
alter
airway
resist
small
airway
lung
way
measur
studi
aim
evalu
chang
measur
ga
trap
particularli
residu
volum
rv
method
prospect
cohort
consecut
patient
sever
asthma
list
bt
two
tertiari
institut
frankston
hospit
macquari
univers
hospit
evalu
three
time
point
name
baselin
week
month
post
complet
procedur
evalu
medic
usag
symptom
score
asthma
control
questionnair
exacerb
histori
obtain
lung
function
evalu
spirometri
ii
ga
diffus
dlco
iii
static
lung
volum
bodi
plethysmographi
result
improv
baselin
month
meanaesd
p
daili
reliev
salbutamol
usag
improv
puff
per
day
p
exacerb
frequenc
mainten
oral
corticosteroid
usag
also
significantli
declin
p
chang
spirometr
paramet
demonstr
dlco
also
unalt
bt
treatment
howev
signific
reduct
ga
trap
observ
rv
fall
predict
predict
pair
test
signific
improv
tlc
frc
also
observ
chang
evid
week
time
period
maintain
month
chang
rv
neg
correl
baselin
indic
greatest
improv
evid
obstruct
patient
bronchial
thermoplasti
appear
improv
ga
trap
effect
greatest
sever
obstruct
patient
improv
may
relat
chang
mechan
properti
small
airway
measur
spirometri
introductionaim
copd
smoke
play
vital
role
develop
nsclc
local
progress
metastasi
nsclc
associ
epitheli
mesenchym
transit
emt
implic
copd
pathogenesi
investig
emt
biomark
vimentin
ncadherin
epitheli
activ
marker
egfr
vascular
marker
typeiv
collagen
surgic
resect
tissu
patient
nsclc
adenoand
squamou
cell
carcinoma
compar
correspond
nontumor
airway
result
egfr
vimentin
ncadherin
express
higher
tumour
cell
peripher
lead
edg
nsclc
compar
central
locat
tumour
cell
subject
p
typeiv
collagen
express
blood
vessel
egfr
express
relat
differenti
statu
p
tnm
stage
p
nsclc
moreov
emt
marker
lead
edg
significantli
relat
airway
emt
activ
peripher
edg
vascular
squamou
cellcarcinoma
significantli
relat
larg
airway
rbm
vascular
p
conclus
egfr
emtrel
protein
express
remark
high
peripher
lead
edg
nsclc
relat
tumour
characterist
associ
poor
prognosi
relationship
emtrel
tumour
biomark
express
airway
epithelium
rbm
provid
background
util
airway
chang
clinic
set
method
qlcss
screen
healthi
volunt
age
extens
current
former
smoke
histori
pack
year
quit
year
prior
scan
result
defin
base
month
followup
falseposit
scan
fp
lung
cancerfre
year
trueposit
tp
fals
neg
global
health
statu
physic
mental
function
assess
use
recal
period
baselin
prescreen
month
month
month
baselin
screen
scan
use
short
form
version
contain
twelv
question
aggreg
summari
measur
mental
compon
summari
mc
physic
compon
summari
pc
calcul
use
factor
weight
deriv
us
gener
popul
sampl
mc
pc
rang
higher
valu
indic
better
health
minim
import
differ
determin
clinic
meaning
differ
mid
half
standard
deviat
sd
mean
result
respons
questionnair
tabl
baselin
mean
sd
mc
pc
respect
mc
gener
popul
norm
pc
norm
small
chang
mid
seen
fp
neg
group
timepoint
figur
larger
chang
seen
tp
group
howev
number
respons
small
conclus
screen
associ
small
measur
chang
global
hrqol
clinic
meaning
differ
particip
neg
fp
scan
grant
support
nhmrc
queensland
govern
smart
state
grant
princ
charl
hospit
foundat
mean
chang
physic
compon
score
mental
compon
score
baselin
introductionaim
exercis
train
deliv
signific
shortterm
improv
function
exercis
capac
symptom
qualiti
life
across
rang
interstiti
lung
diseas
ild
extent
individu
experi
clinic
signific
benefit
studi
aim
establish
proport
patient
achiev
minim
import
differ
mid
walk
distanc
dyspnoea
fatigu
domain
chronic
respiratori
questionnair
crq
method
data
particip
ild
idiopath
pulmonari
fibrosi
ipf
asbestosi
connect
tissu
diseaserel
ild
ctdild
ild
aetiolog
randomis
either
eight
week
supervis
exercis
train
usual
care
review
compar
percentag
patient
achiev
mid
ild
crq
dyspnoea
point
crq
fatigu
point
exercis
train
control
group
entir
ild
popul
subgroup
ipf
asbestosi
ctdild
use
pearson
chi
result
follow
exercis
train
least
third
particip
achiev
improv
exceed
mid
increas
ipf
asbestosi
subgroup
respect
see
tabl
compar
control
group
greater
percentag
particip
achiev
improv
exceed
mid
crq
dyspnoea
fatigu
entir
ild
sampl
ipf
asbestosi
significantli
greater
control
group
crq
fatigu
improv
exceed
mid
limit
ctdild
like
occur
crq
dyspnoea
fatigu
conclus
third
half
particip
ild
achiev
clinic
meaning
improv
follow
exercis
train
includ
ipf
devast
ild
fatigu
appear
respons
chang
dyspnoea
grant
support
abstract
fund
at
foundationpulmonari
fibrosi
foundat
nation
health
medic
research
council
eiren
luca
foundat
institut
breath
sleep
p
compar
control
group
ild
interstiti
lung
diseas
ctd
ild
connect
tissu
diseaserel
ild
ipf
idiopath
pulmonari
fibrosi
editori
materi
organ
asian
pacif
societi
respirolog
copyright
individu
abstract
remain
author
pool
data
tomorrow
inpulsi
trial
incid
major
advers
cv
event
similar
nintedanib
placebo
group
patient
higher
lower
cv
risk
baselin
grant
support
studi
fund
boehring
ingelheim
declar
interest
statement
tc
receiv
unrestrict
educ
grant
travel
assist
serv
advisori
board
boehring
ingelheim
roch
product
ltd
receiv
unrestrict
educ
grant
intermun
pharmaceut
serv
advisori
board
astra
zeneca
receiv
institut
grant
centacor
immunework
actelion
nation
institut
health
conduct
clinic
trial
ipf
support
nation
institut
health
nation
heart
lung
blood
institut
mw
receiv
speaker
advisori
board
fee
paid
institut
intermun
boehring
ingelheim
roch
unrestrict
research
grant
paid
institut
intermun
roch
mk
receiv
grant
person
fee
roch
boehring
ingelheim
gsk
gilead
promet
alkerm
grant
actelion
respivert
synairgen
person
fee
astrazeneca
genoa
fb
receiv
grant
honoraria
rochegenentech
intermun
boehring
ingelheim
serendex
sekisui
diagnost
lm
dw
employe
boehring
ingelheim
conclus
rang
intervent
particularli
involv
physic
activ
counsel
improv
physic
activ
measur
daili
step
result
suggest
target
intervent
may
use
improv
physic
activ
peopl
copd
